{"2a57289454c2426776c0a86fb08e646f98b65513": [["Influenza A (H1N1) infection is associated with significant economic costs and deaths.", [["Influenza A (H1N1) infection", "DISEASE", 0, 28], ["deaths", "DISEASE", 79, 85], ["Influenza A (H1N1)", "ORGANISM", 0, 18], ["Influenza A (H1N1", "SPECIES", 0, 17], ["Influenza A (H1N1)", "SPECIES", 0, 18], ["Influenza A (H1N1) infection", "PROBLEM", 0, 28]]], ["1 H1N1 transmits from person to person mainly through coughing, sneezing, and close body contact.", [["body", "ANATOMY", 84, 88], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["person", "SPECIES", 22, 28], ["person", "SPECIES", 32, 38], ["coughing", "PROBLEM", 54, 62], ["sneezing", "PROBLEM", 64, 72]]], ["2 Staying vigilant by adopting appropriate preventive precautions, such as washing hands and wearing masks, is of crucial importance, especially for vulnerable individuals, such as children and elderly adults.", [["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["preventive precautions", "TREATMENT", 43, 65]]], ["3 The first confirmed H1N1 case in Asia was identified on May 1, 2009 , in Hong Kong.", [["H1N1", "OBSERVATION", 22, 26]]], ["The first community H1N1 case and first H1N1-related death in Hong Kong were reported on June 12, 2009, and July 10, 2009, 4 respectively.", [["H1N1", "DISEASE", 40, 44], ["death", "DISEASE", 53, 58], ["first H1N1-related death", "PROBLEM", 34, 58]]], ["Perceptions and behaviors related to the 2009 H1N1 pandemic have been investigated in the Hong Kong general population, 5,6 but data for students are not available.", [["H1N1", "DISEASE", 46, 50]]], ["The present study investigated the knowledge, risk perceptions, and preventive precautions of H1N1 in Hong Kong students during the 2009 pandemic.METHODSA convenience sample of 288 Hong Kong secondary school students (aged 14-18 years) was surveyed during the 2009 H1N1 pandemic (May 12-22, 2009) with a response rate of 98%.", [["H1N1", "DISEASE", 94, 98], ["H1N1", "DISEASE", 265, 269], ["The present study", "TEST", 0, 17], ["H1N1", "PROBLEM", 94, 98], ["a response rate", "TEST", 302, 317]]], ["The students reported their demographic information (sex and age) and knowledge, risk perceptions, and preventive precautions regarding H1N1.", [["H1N1", "DISEASE", 136, 140], ["preventive precautions", "TREATMENT", 103, 125], ["H1N1", "PROBLEM", 136, 140]]], ["Ethical approval for the study was granted by the University Ethics Committee.METHODSThe students were provided with a symptom checklist (yes/no answers) on which to indicate the presence of influenza symptoms, including headache, muscle pain, cough, difficulty breathing, dizziness, sore throat, chills, and fever, within the previous 14 days.", [["muscle", "ANATOMY", 231, 237], ["influenza symptoms", "DISEASE", 191, 209], ["headache", "DISEASE", 221, 229], ["muscle pain", "DISEASE", 231, 242], ["cough", "DISEASE", 244, 249], ["difficulty breathing", "DISEASE", 251, 271], ["dizziness", "DISEASE", 273, 282], ["sore throat", "DISEASE", 284, 295], ["chills", "DISEASE", 297, 303], ["fever", "DISEASE", 309, 314], ["muscle", "ORGAN", 231, 237], ["the study", "TEST", 21, 30], ["a symptom checklist", "TEST", 117, 136], ["influenza symptoms", "PROBLEM", 191, 209], ["headache", "PROBLEM", 221, 229], ["muscle pain", "PROBLEM", 231, 242], ["cough", "PROBLEM", 244, 249], ["difficulty breathing", "PROBLEM", 251, 271], ["dizziness", "PROBLEM", 273, 282], ["sore throat", "PROBLEM", 284, 295], ["chills", "PROBLEM", 297, 303], ["fever", "PROBLEM", 309, 314], ["influenza", "OBSERVATION", 191, 200], ["muscle", "ANATOMY", 231, 237], ["sore throat", "ANATOMY", 284, 295], ["chills", "OBSERVATION", 297, 303], ["fever", "OBSERVATION", 309, 314]]], ["They were also asked about experiencing influenza in the previous 14 days.", [["influenza", "DISEASE", 40, 49], ["influenza", "PROBLEM", 40, 49]]], ["Specific questions assessing knowledge of the major routes of H1N1 transmission included the following: (1) \"Do you think H1N1 could transmit via the airborne route?\"; (2) \"Do you think H1N1 could transmit via water?\"; and (3) \"Do you think H1N1 could transmit via body contact?\" with responses of \"agree/ disagree/not sure.\"", [["body", "ANATOMY", 265, 269], ["H1N1", "DISEASE", 62, 66], ["H1N1", "DISEASE", 122, 126], ["H1N1", "DISEASE", 186, 190], ["H1N1", "DISEASE", 241, 245], ["H1N1", "ORGANISM", 241, 245], ["body", "ORGANISM_SUBDIVISION", 265, 269], ["H1N1", "PROBLEM", 122, 126]]], ["An indication variable (1 item/2 items/all 3 items) was created to determine the number of correct answer (agreeing with the statements) regarding knowledge of routes of H1N1 transmission.", [["H1N1", "DISEASE", 170, 174], ["H1N1 transmission", "PROBLEM", 170, 187], ["H1N1", "OBSERVATION", 170, 174]]], ["Risk perception assessment included perceived risks of H1N1 infection, perceived risks of H1N1 infection compared with the 2003 Severe Acute Respiratory Syndrome (SARS) pandemic, and perceived risks of H1N1 infection compared with the 2007 H5N1 pandemic.METHODSAdoption of the following preventive precautions during the H1N1 pandemic was investigated: (1) washing hands with soap or alcohol pad, (2) washing hands immediately after sneezing or coughing, (3) washing hands after contacting contaminated objects, (4) covering mouth when coughing or sneezing, and (5) wearing a mask.", [["mouth", "ANATOMY", 525, 530], ["H1N1 infection", "DISEASE", 55, 69], ["H1N1 infection", "DISEASE", 90, 104], ["Acute Respiratory Syndrome (SARS) pandemic", "DISEASE", 135, 177], ["H1N1 infection", "DISEASE", 202, 216], ["H5N1", "DISEASE", 240, 244], ["H1N1", "DISEASE", 321, 325], ["alcohol", "CHEMICAL", 384, 391], ["alcohol", "CHEMICAL", 384, 391], ["mouth", "ORGANISM_SUBDIVISION", 525, 530], ["Risk perception assessment", "TEST", 0, 26], ["H1N1 infection", "PROBLEM", 55, 69], ["H1N1 infection", "PROBLEM", 90, 104], ["Severe Acute Respiratory Syndrome", "PROBLEM", 128, 161], ["pandemic", "PROBLEM", 169, 177], ["H1N1 infection", "PROBLEM", 202, 216], ["METHODSAdoption", "TREATMENT", 254, 269], ["preventive precautions", "TREATMENT", 287, 309], ["the H1N1 pandemic", "TREATMENT", 317, 334], ["alcohol pad", "TREATMENT", 384, 395], ["sneezing", "PROBLEM", 433, 441], ["coughing", "PROBLEM", 445, 453], ["coughing", "PROBLEM", 536, 544], ["sneezing", "PROBLEM", 548, 556], ["a mask", "TREATMENT", 574, 580], ["H1N1", "OBSERVATION", 90, 94], ["Severe", "OBSERVATION_MODIFIER", 128, 134], ["Acute", "OBSERVATION_MODIFIER", 135, 140], ["Respiratory Syndrome", "OBSERVATION", 141, 161], ["H1N1", "OBSERVATION", 202, 206], ["mouth", "ANATOMY", 525, 530]]], ["The number of preventive precautions reported by the student was then recorded (0-1 item/2-3 items/4-5 items).", [["preventive precautions", "TREATMENT", 14, 36]]], ["The regression models revealed that adoption of 4-5 preventive precautions was significantly related to female sex (adjusted OR, 2.63; 95% CI, 1.47-4.16) and correct answers to all questions about knowledge of the major routes of H1N1 transmission (adjusted OR, 2.41; 95% CI, 1.39-4.17) ( Table 1) .", [["H1N1", "DISEASE", 230, 234], ["The regression models", "TEST", 0, 21], ["preventive precautions", "TREATMENT", 52, 74], ["CI", "TEST", 139, 141], ["CI", "TEST", 272, 274]]], ["A high absolute perceived risk of H1N1 infection (adjusted OR, 1.81; 95% CI, 1.10-2.98), but not a comparative perceived risk of H1N1 infection, was significantly associated with adoption of most preventive precautions.DISCUSSIONIn general, Hong Kong students have poor knowledge of the major routes of H1N1 transmission.", [["H1N1 infection", "DISEASE", 34, 48], ["H1N1 infection", "DISEASE", 129, 143], ["H1N1", "DISEASE", 303, 307], ["H1N1", "SPECIES", 129, 133], ["H1N1 infection", "PROBLEM", 34, 48], ["CI", "TEST", 73, 75], ["H1N1 infection", "PROBLEM", 129, 143], ["most preventive precautions", "TREATMENT", 191, 218], ["high absolute", "OBSERVATION_MODIFIER", 2, 15], ["H1N1", "OBSERVATION_MODIFIER", 34, 38], ["infection", "OBSERVATION", 39, 48], ["H1N1", "OBSERVATION_MODIFIER", 129, 133], ["infection", "OBSERVATION", 134, 143], ["H1N1", "OBSERVATION", 303, 307]]], ["Most students also perceived a lower risk of H1N1 infection compared with the 2003 SARS and 2007 H5N1 pandemics.", [["infection", "DISEASE", 50, 59], ["SARS", "DISEASE", 83, 87], ["H5N1 pandemics", "DISEASE", 97, 111], ["H1N1 infection", "PROBLEM", 45, 59], ["H1N1", "OBSERVATION", 45, 49], ["infection", "OBSERVATION", 50, 59]]], ["The prevalence of mask wearing in these students was lower than that in Hong Kong and Singapore university students during the H1N1 pandemic.", [["H1N1", "DISEASE", 127, 131], ["mask", "TREATMENT", 18, 22], ["the H1N1 pandemic", "PROBLEM", 123, 140]]], ["7 Female students were more likely than male students to adopt preventive precautions, likely related to the higher perceptions of H1N1 risk reported by females.", [["H1N1", "DISEASE", 131, 135], ["preventive precautions", "TREATMENT", 63, 85], ["H1N1 risk", "PROBLEM", 131, 140]]], ["8 Furthermore, adoption of H1N1 preventive precautions was associated with better knowledge of transmission and perceived high risks of infection, as found in the Western 9 and Chinese 10 general populations.DISCUSSIONThe results of this research should be interpreted with caution.", [["infection", "DISEASE", 136, 145], ["H1N1", "ORGANISM", 27, 31], ["H1N1", "SPECIES", 27, 31], ["H1N1 preventive precautions", "TREATMENT", 27, 54], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["Nevertheless, Hong Kong students represent a unique population that experienced both SARS and H5N1 outbreaks before the 2009 H1N1 pandemic.", [["SARS", "DISEASE", 85, 89], ["H5N1", "DISEASE", 94, 98], ["H1N1", "DISEASE", 125, 129], ["SARS", "PROBLEM", 85, 89], ["H5N1 outbreaks", "PROBLEM", 94, 108]]], ["Thus, our findings are of value to those devising and evaluating strategies to combat future global pandemics.", [["global pandemics", "PROBLEM", 93, 109]]], ["Another limitation of this study is the self-reported nature of the data.", [["this study", "TEST", 22, 32]]], ["However, our internal validity test demonstrated a significant and positive correlation between the number of influenza symptoms and experiencing influenza in the previous 14 days.DISCUSSIONIn conclusion, our data indicate that most Hong Kong students have insufficient knowledge of H1N1 infection and failed to adopt sufficient preventive precautions during the H1N1 pandemic.", [["influenza symptoms", "DISEASE", 110, 128], ["influenza", "DISEASE", 146, 155], ["H1N1 infection", "DISEASE", 283, 297], ["H1N1", "ORGANISM", 283, 287], ["our internal validity test", "TEST", 9, 35], ["influenza symptoms", "PROBLEM", 110, 128], ["influenza", "PROBLEM", 146, 155], ["H1N1 infection", "PROBLEM", 283, 297], ["preventive precautions", "TREATMENT", 329, 351], ["the H1N1 pandemic", "PROBLEM", 359, 376], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["positive", "OBSERVATION", 67, 75], ["infection", "OBSERVATION", 288, 297]]], ["Health education programs focusing on prevention of infectious diseases are warranted.", [["infectious diseases", "DISEASE", 52, 71], ["Health education programs", "TREATMENT", 0, 25], ["infectious diseases", "PROBLEM", 52, 71]]]], "PMC7332962": [["Not good enoughIn a linked paper, Bastos and colleagues (doi:10.1136/bmj.m2516) provide a much needed review of the performance of serological assays to accurately detect antibodies to SARS-CoV-2.2 They meta-analyzed 40 studies according to type of antibody test (enzyme linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), and chemiluminescent immunoassays (CLIAs)), and for each type, determined the average or pooled sensitivity and specificity and assessed the studies for risk of bias.", [["SARS", "DISEASE", 185, 189], ["SARS-CoV", "ORGANISM", 185, 193], ["antibodies", "PROTEIN", 171, 181], ["SARS-CoV", "SPECIES", 185, 193], ["serological assays", "TEST", 131, 149], ["antibodies", "TEST", 171, 181], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["antibody test", "TEST", 249, 262], ["enzyme", "TEST", 264, 270], ["immunosorbent assays", "TEST", 278, 298], ["ELISAs", "TEST", 300, 306], ["lateral flow immunoassays", "TEST", 309, 334], ["LFIAs", "TEST", 336, 341], ["chemiluminescent immunoassays", "TEST", 348, 377], ["the studies", "TEST", 481, 492], ["bias", "PROBLEM", 505, 509]]], ["Only four of the 40 studies included outpatients and only two studies assessed LFIAs at the point of care.Not good enoughThe pooled sensitivities had a wide range, with higher sensitivity in the CLIAs (97.8%) and lowest in the LFIAs (66.0%) and were higher with increased time after symptom onset.", [["two studies", "TEST", 58, 69], ["The pooled sensitivities", "TEST", 121, 145], ["the CLIAs", "TEST", 191, 200], ["the LFIAs", "TEST", 223, 232], ["symptom onset", "PROBLEM", 283, 296]]], ["The range for specificities was narrower, from 96.6% to 99.7%.", [["specificities", "TEST", 14, 27]]], ["The risk of patient selection bias affected nearly every study.Not good enoughIt is important to keep in mind that pooling sensitivities makes it difficult to determine how well tests perform at detecting antibody early or late in the course of illness (reported as 26.7% for samples collected during the first week versus 78.4% for samples collected beyond the third week for ELISAs).", [["samples", "ANATOMY", 276, 283], ["samples", "ANATOMY", 333, 340], ["illness", "DISEASE", 245, 252], ["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["pooling sensitivities", "PROBLEM", 115, 136], ["illness", "PROBLEM", 245, 252], ["samples", "TEST", 333, 340], ["ELISAs", "TEST", 377, 383]]], ["Pooling also hinders the ability to identify individual tests that might perform well in testing algorithms, described below.", [["individual tests", "TEST", 45, 61], ["testing algorithms", "TEST", 89, 107]]], ["Ideally, test performance should be compared according to the viral antigen used in each assay, such as the N nucleocapsid or the S spike protein, since antibodies against the spike protein are thought to correlate with neutralizing titers.3 Nonetheless, the key message of the review aligns with the conclusion of another systematic review4 published last week: serologic assays for SARS-CoV-2 antibodies, especially point-of-care tests, are not ready for widespread use by clinicians, the general public, or policy makers.Not good enoughIt is unlikely that any single serologic test will provide the kind of reliable and accurate information that are needed to fully understand the current pandemic.", [["antibodies against the spike protein", "GENE_OR_GENE_PRODUCT", 153, 189], ["SARS-CoV-2", "ORGANISM", 384, 394], ["viral antigen", "PROTEIN", 62, 75], ["N nucleocapsid", "PROTEIN", 108, 122], ["S spike protein", "PROTEIN", 130, 145], ["antibodies", "PROTEIN", 153, 163], ["spike protein", "PROTEIN", 176, 189], ["SARS-CoV-2 antibodies", "PROTEIN", 384, 405], ["SARS-CoV", "SPECIES", 384, 392], ["test performance", "TEST", 9, 25], ["the viral antigen", "TEST", 58, 75], ["the N nucleocapsid", "PROBLEM", 104, 122], ["the S spike protein", "TEST", 126, 145], ["antibodies", "TREATMENT", 153, 163], ["the spike protein", "PROBLEM", 172, 189], ["neutralizing titers", "PROBLEM", 220, 239], ["serologic assays", "TEST", 363, 379], ["SARS", "TEST", 384, 388], ["CoV", "TEST", 389, 392], ["antibodies", "TEST", 395, 405], ["any single serologic test", "TEST", 559, 584], ["neutralizing titers", "OBSERVATION", 220, 239]]], ["As Bastos and colleagues and others have indicated,5 tests with low specificity provide more false positives than true positives in low prevalence settings, resulting in unacceptably low positive predictive values.", [["5 tests", "TEST", 51, 58], ["unacceptably low positive predictive values", "PROBLEM", 170, 213], ["low prevalence", "OBSERVATION_MODIFIER", 132, 146]]], ["To overcome the poor performance of a single serologic test, an algorithm should be considered that combines two or more tests (eg,6).", [["a single serologic test", "TEST", 36, 59], ["an algorithm", "TEST", 61, 73]]], ["For example, in a 5% prevalence setting, screening with one of the more sensitive ELISAs reviewed by Bastos and colleagues (96.0% sensitivity, 99.2% specificity)7 and then using a more specific test (85.0% sensitivity, 100% specificity)8 as the confirmatory test would increase positive predictive value from 55% to 100%.9 Such an algorithm would still fail to identify antibodies in samples collected within the first 14 days of symptom onset and require follow-up testing at a later date (more than three weeks after symptom onset).Independent evaluationIn the early months of the outbreak, the global market was flooded with antibody tests of unproven test performance, and various governments, including those of the UK and India, purchased large quantities of ineffective antibody tests.101112 In the US, the Food and Drug Administration reversed course in May and mandated emergency use authorizations for all commercially available serologic test kits with a test performance of 90% or more sensitivity and 95% or more specificity,13 but the damage had been done and contributed to surveillance data of uneven quality.", [["samples", "ANATOMY", 384, 391], ["antibodies", "PROTEIN", 370, 380], ["screening", "TEST", 41, 50], ["sensitivity", "TEST", 130, 141], ["sensitivity", "TEST", 206, 217], ["the confirmatory test", "TEST", 241, 262], ["an algorithm", "TEST", 328, 340], ["antibodies in samples", "PROBLEM", 370, 391], ["symptom onset", "PROBLEM", 430, 443], ["follow-up testing", "TEST", 456, 473], ["Independent evaluation", "TEST", 534, 556], ["antibody tests", "TEST", 628, 642], ["ineffective antibody tests", "PROBLEM", 765, 791], ["serologic test kits", "TEST", 939, 958], ["a test performance", "TEST", 964, 982], ["the damage", "PROBLEM", 1045, 1055], ["surveillance data", "TEST", 1089, 1106]]], ["Critical independent evaluations of antibody tests are currently underway by the FDA and other organizations141516 to provide researchers, public health officials, and others with better data for decision making.", [["antibody tests", "TEST", 36, 50]]], ["Ideally, these evaluations should all use the same specimen panels containing reverse transcriptase polymerase chain reaction confirmed SARS-CoV-2 positive and negative plasma.", [["plasma", "ANATOMY", 169, 175], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["reverse transcriptase", "PROTEIN", 78, 99], ["these evaluations", "TEST", 9, 26], ["the same specimen panels", "TEST", 42, 66], ["reverse transcriptase polymerase chain reaction", "TEST", 78, 125], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144]]], ["Such specimen panels are a valuable tool for both test kit developers and evaluators, and global health institutions should make them widely available.Independent evaluationAs this review makes clear, there is more work to do on serologic testing.", [["Such specimen panels", "TEST", 0, 20], ["evaluators", "TEST", 74, 84], ["Independent evaluation", "TEST", 151, 173], ["serologic testing", "TEST", 229, 246]]], ["Assays must be optimized further, independently validated, and used in an algorithm format to achieve the highest possible accuracy for decision making, especially at an individual level.Independent evaluationHigh quality antibody tests have the potential to provide important information about prior infection, and the prevalence of antibodies in a population might help us to understand the extent of the epidemic and the role of transmission from asymptomatic individuals.", [["infection", "DISEASE", 301, 310], ["antibodies", "PROTEIN", 334, 344], ["Assays", "TEST", 0, 6], ["Independent evaluationHigh quality antibody tests", "TEST", 187, 236], ["prior infection", "PROBLEM", 295, 310], ["antibodies", "PROBLEM", 334, 344], ["asymptomatic individuals", "PROBLEM", 450, 474], ["infection", "OBSERVATION", 301, 310]]], ["Further research is needed to address fundamental questions about the presence of antibodies and the degree and durability of protection.", [["antibodies", "PROTEIN", 82, 92], ["antibodies", "PROBLEM", 82, 92]]], ["Until then, even the most optimal serologic test will be of limited utility.", [["serologic test", "TEST", 34, 48]]]], "PMC7113876": [["Porcine epidemic diarrhea (PED), a serious and highly contagious swine disease, is characterized clinically by vomiting, diarrhea, and dehydration in suckling piglets (Van Reeth and Pensaert, 1994).", [["Porcine epidemic diarrhea", "DISEASE", 0, 25], ["PED", "DISEASE", 27, 30], ["swine disease", "DISEASE", 65, 78], ["vomiting", "DISEASE", 111, 119], ["diarrhea", "DISEASE", 121, 129], ["dehydration", "DISEASE", 135, 146], ["piglets", "ORGANISM", 159, 166], ["Porcine", "SPECIES", 0, 7], ["swine", "SPECIES", 65, 70], ["piglets", "SPECIES", 159, 166], ["Porcine epidemic diarrhea (PED)", "SPECIES", 0, 31], ["swine", "SPECIES", 65, 70], ["Porcine epidemic diarrhea", "PROBLEM", 0, 25], ["a serious and highly contagious swine disease", "PROBLEM", 33, 78], ["vomiting", "PROBLEM", 111, 119], ["diarrhea", "PROBLEM", 121, 129], ["dehydration", "PROBLEM", 135, 146], ["epidemic", "OBSERVATION_MODIFIER", 8, 16], ["diarrhea", "OBSERVATION", 17, 25], ["highly", "OBSERVATION_MODIFIER", 47, 53], ["contagious", "OBSERVATION_MODIFIER", 54, 64], ["swine disease", "OBSERVATION", 65, 78], ["diarrhea", "OBSERVATION", 121, 129], ["dehydration", "OBSERVATION_MODIFIER", 135, 146]]], ["Its etiologic agent, porcine epidemic diarrhea virus (PEDV) belongs to the genus Coronavirus of the family Coronaviridae, and is an enveloped, single-stranded RNA virus.", [["porcine epidemic diarrhea virus", "DISEASE", 21, 52], ["porcine epidemic diarrhea virus", "ORGANISM", 21, 52], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 107, 120], ["porcine epidemic diarrhea virus", "SPECIES", 21, 52], ["porcine epidemic diarrhea virus", "SPECIES", 21, 52], ["PEDV", "SPECIES", 54, 58], ["porcine epidemic diarrhea virus", "PROBLEM", 21, 52], ["single-stranded RNA virus", "PROBLEM", 143, 168], ["porcine", "OBSERVATION_MODIFIER", 21, 28], ["epidemic", "OBSERVATION_MODIFIER", 29, 37], ["genus Coronavirus", "ANATOMY", 75, 92]]], ["The viral disease was discovered in the United Kingdom in 1971 and subsequently reported in many swine-producing countries of Europe and Asia (Puranaveja et al., 2009).", [["viral disease", "DISEASE", 4, 17], ["The viral disease", "PROBLEM", 0, 17], ["viral disease", "OBSERVATION", 4, 17]]]], "343a6527c0e3660a256d8e04eb563549c0fa506b": [["Dear Editor,We constantly read with interest the current scientific debate around COVID-19 emergency management.", [["emergency management", "TREATMENT", 91, 111]]], ["Beside specific new therapeutic options, this emergency has drawn the attention of the medical scientific community in reconsidering our current knowledge regarding the physiopathology of acute respiratory distress syndrome (ARDS), sepsis and the choice of antiviral drugs and antibiotics (in case of superimposed bacterial pneumonia).", [["respiratory", "ANATOMY", 194, 205], ["acute respiratory distress syndrome", "DISEASE", 188, 223], ["ARDS", "DISEASE", 225, 229], ["sepsis", "DISEASE", 232, 238], ["bacterial pneumonia", "DISEASE", 314, 333], ["acute respiratory distress syndrome", "PROBLEM", 188, 223], ["ARDS", "PROBLEM", 225, 229], ["sepsis", "PROBLEM", 232, 238], ["antiviral drugs", "TREATMENT", 257, 272], ["antibiotics", "TREATMENT", 277, 288], ["superimposed bacterial pneumonia", "PROBLEM", 301, 333], ["new", "OBSERVATION_MODIFIER", 16, 19], ["therapeutic", "OBSERVATION_MODIFIER", 20, 31], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["respiratory distress", "OBSERVATION", 194, 214], ["sepsis", "OBSERVATION", 232, 238], ["bacterial", "OBSERVATION_MODIFIER", 314, 323], ["pneumonia", "OBSERVATION", 324, 333]]], ["Noteworthy, clinical presentation of COVID-19 pneumonia and the associated respiratory failure is different from the classic ARDS [1, 2] .", [["respiratory", "ANATOMY", 75, 86], ["pneumonia", "DISEASE", 46, 55], ["respiratory failure", "DISEASE", 75, 94], ["ARDS", "DISEASE", 125, 129], ["COVID", "TEST", 37, 42], ["pneumonia", "PROBLEM", 46, 55], ["the associated respiratory failure", "PROBLEM", 60, 94], ["the classic ARDS", "PROBLEM", 113, 129], ["pneumonia", "OBSERVATION", 46, 55], ["respiratory failure", "OBSERVATION", 75, 94], ["different", "OBSERVATION_MODIFIER", 98, 107], ["ARDS", "OBSERVATION", 125, 129]]], ["Consequently, the debate around the role and the possible effects of non-invasive ventilation, mechanical ventilation, prone position and the use of PEEP is still ongoing [1] [2] [3] .", [["non-invasive ventilation", "TREATMENT", 69, 93], ["mechanical ventilation", "TREATMENT", 95, 117], ["PEEP", "TREATMENT", 149, 153], ["mechanical ventilation", "OBSERVATION", 95, 117]]], ["Understandably, mechanical ventilation modes and the weaning process represents fundamental aspects of intensive care management of these patients; however, the recent improvements in our understanding of the COVID-19 pathogenesis have move our attention also to several other complications related to this infection (i.e., thrombosis, myocarditis and neuropsychiatric disorders) [4] [5] [6] .Dear Editor,Nevertheless, this pandemic emergency had forced us to face specific new challenges.", [["infection", "DISEASE", 307, 316], ["thrombosis", "DISEASE", 324, 334], ["myocarditis", "DISEASE", 336, 347], ["neuropsychiatric disorders", "DISEASE", 352, 378], ["patients", "ORGANISM", 138, 146], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 380, 391], ["patients", "SPECIES", 138, 146], ["mechanical ventilation modes", "TREATMENT", 16, 44], ["the weaning process", "TREATMENT", 49, 68], ["intensive care management", "TREATMENT", 103, 128], ["the COVID", "TEST", 205, 214], ["several other complications", "PROBLEM", 263, 290], ["this infection", "PROBLEM", 302, 316], ["thrombosis", "PROBLEM", 324, 334], ["myocarditis", "PROBLEM", 336, 347], ["neuropsychiatric disorders)", "PROBLEM", 352, 379], ["mechanical ventilation", "OBSERVATION", 16, 38], ["infection", "OBSERVATION", 307, 316], ["thrombosis", "OBSERVATION", 324, 334], ["myocarditis", "OBSERVATION", 336, 347]]], ["Besides general medical management, a major aspect of the crisis was to reconsider the general organization of our hospital and the personnel shift [7] .", [["general medical management", "TREATMENT", 8, 34], ["the crisis", "PROBLEM", 54, 64]]], ["Our health care system had to deal with the need for new intensive care units in order to cope with the increasing number of patients positive for COVID-19.", [["COVID-19", "CHEMICAL", 147, 155], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["new intensive care units", "TREATMENT", 53, 77], ["COVID", "TEST", 147, 152]]], ["In addition, the COVID-19 pneumonia is characterized by the need for prolonged ventilatory support and a slow and challenging weaning process.", [["pneumonia", "DISEASE", 26, 35], ["COVID-19", "SPECIES", 17, 25], ["the COVID", "TEST", 13, 22], ["pneumonia", "PROBLEM", 26, 35], ["prolonged ventilatory support", "TREATMENT", 69, 98], ["a slow and challenging weaning process", "TREATMENT", 103, 141], ["pneumonia", "OBSERVATION", 26, 35], ["ventilatory support", "OBSERVATION", 79, 98]]], ["This fundamental and peculiar aspect has to take into account in reconsidering the organization of our hospital.", [["peculiar", "OBSERVATION_MODIFIER", 21, 29]]], ["Consequently, after creating new intensive care units to receive the unstable and severe patients, we consider it vital to create new sub-intensive and respiratory intensive care units, where intensivists, pneumologists and respiratory therapists can work as a team during the weaning process.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["the weaning process", "TREATMENT", 273, 292], ["severe", "OBSERVATION_MODIFIER", 82, 88]]], ["This organization can help to discharge in advance patients from intensive care unit as soon as the weaning process has begun and clinical parameters are stable.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["the weaning process", "TREATMENT", 96, 115], ["clinical parameters", "TEST", 130, 149], ["stable", "OBSERVATION_MODIFIER", 154, 160]]], ["This consent to faster availability of intensive care beds.", [["intensive care beds", "TREATMENT", 39, 58]]], ["Even more, this organization allows to reserve the highest level of treatment support for the most severe critical care patients and, at the same time, to create a unique and specialized setting where patients can be followed during the delicate weaning process [8] .", [["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 201, 209], ["treatment support", "TREATMENT", 68, 85]]], ["In this specific setting, tracheostomy may play a central role.", [["tracheostomy", "TREATMENT", 26, 38], ["tracheostomy", "OBSERVATION", 26, 38]]], ["As already stated, characteristics of COVID-19 pneumonia management are represented by lengthy mechanical ventilation and difficult weaning; two main indications for tracheostomy.", [["pneumonia", "DISEASE", 47, 56], ["COVID", "TEST", 38, 43], ["pneumonia management", "TREATMENT", 47, 67], ["lengthy mechanical ventilation", "TREATMENT", 87, 117], ["difficult weaning", "TREATMENT", 122, 139], ["tracheostomy", "TREATMENT", 166, 178], ["pneumonia", "OBSERVATION", 47, 56], ["mechanical ventilation", "OBSERVATION", 95, 117], ["tracheostomy", "OBSERVATION", 166, 178]]], ["With the increasing demand for mechanical ventilator and intensive care beds, tracheostomy should be considered as soon as the most severe phase of the clinical course of pneumonia has been overcome.", [["pneumonia", "DISEASE", 171, 180], ["mechanical ventilator", "TREATMENT", 31, 52], ["intensive care beds", "TREATMENT", 57, 76], ["tracheostomy", "TREATMENT", 78, 90], ["pneumonia", "PROBLEM", 171, 180], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["mechanical ventilator", "OBSERVATION", 31, 52], ["tracheostomy", "OBSERVATION", 78, 90], ["pneumonia", "OBSERVATION", 171, 180]]], ["In fact, the several and well-known advantages in performing a tracheostomy in the general management of critical patients becomes even more important nowadays.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["a tracheostomy", "TREATMENT", 61, 75], ["the general management", "TREATMENT", 79, 101]]], ["Above all, the reduction in sedation, improved patient comfort and airway safety (reduced risk of tube dislocation and accidental extubation) play a crucial role during the weaning process as well as during nursing care.", [["airway", "ANATOMY", 67, 73], ["tube", "ANATOMY", 98, 102], ["dislocation", "DISEASE", 103, 114], ["patient", "ORGANISM", 47, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["tube", "TISSUE", 98, 102], ["patient", "SPECIES", 47, 54], ["sedation", "TREATMENT", 28, 36], ["airway safety", "TREATMENT", 67, 80], ["tube dislocation", "PROBLEM", 98, 114], ["accidental extubation", "TREATMENT", 119, 140], ["the weaning process", "TREATMENT", 169, 188], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["airway", "ANATOMY", 67, 73], ["tube dislocation", "OBSERVATION", 98, 114]]], ["Furthermore, tracheostomy presents beneficial effects on the respiratory system.", [["respiratory system", "ANATOMY", 61, 79], ["tracheostomy", "TREATMENT", 13, 25], ["tracheostomy", "OBSERVATION", 13, 25], ["respiratory system", "ANATOMY", 61, 79]]], ["In comparison with endotracheal tube, the tracheostomy cannula presents a larger inner diameter and a minor length leading to a decrease in dead space, airway resistance and to a reduction in the work of breathing [9] .", [["endotracheal tube", "ANATOMY", 19, 36], ["inner", "ANATOMY", 81, 86], ["airway", "ANATOMY", 152, 158], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 19, 36], ["inner", "TISSUE", 81, 86], ["airway", "MULTI-TISSUE_STRUCTURE", 152, 158], ["endotracheal tube", "TREATMENT", 19, 36], ["the tracheostomy cannula", "TREATMENT", 38, 62], ["a larger inner diameter", "TREATMENT", 72, 95], ["a decrease in dead space", "PROBLEM", 126, 150], ["airway resistance", "PROBLEM", 152, 169], ["endotracheal tube", "OBSERVATION", 19, 36], ["tracheostomy cannula", "OBSERVATION", 42, 62], ["larger", "OBSERVATION_MODIFIER", 74, 80], ["inner", "OBSERVATION_MODIFIER", 81, 86], ["diameter", "OBSERVATION_MODIFIER", 87, 95], ["minor", "OBSERVATION_MODIFIER", 102, 107], ["length", "OBSERVATION_MODIFIER", 108, 114], ["decrease", "OBSERVATION_MODIFIER", 128, 136], ["dead space", "OBSERVATION", 140, 150], ["airway resistance", "OBSERVATION", 152, 169], ["reduction", "OBSERVATION_MODIFIER", 179, 188]]], ["Even more, tracheostomy optimizes synchrony with the ventilator; another important aspect during the weaning process.", [["tracheostomy", "TREATMENT", 11, 23], ["the ventilator", "TREATMENT", 49, 63], ["the weaning process", "TREATMENT", 97, 116], ["tracheostomy", "OBSERVATION", 11, 23]]], ["Of course, the operators have to keep in mind that the exposure during the tracheostomy procedure is high.", [["the tracheostomy procedure", "TREATMENT", 71, 97], ["tracheostomy", "OBSERVATION", 75, 87]]], ["Consequently, the decision and the timing of performing a tracheostomy should be taken with awareness of these risks.", [["a tracheostomy", "TREATMENT", 56, 70]]], ["Preserve the quality of patient care level has to be outweighed with the fundamental aspect of warrant healthcare safety.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31]]], ["In these lights, any precaution to reduce aerosol contamination has to be strictly followed during the procedure [10] .", [["any precaution", "TREATMENT", 17, 31], ["aerosol contamination", "PROBLEM", 42, 63], ["the procedure", "TREATMENT", 99, 112]]], ["The use of personal Protective Equipment (PPE), HEPA filter, closed line suction, non-fenestrated cuffed cannula and sealed port for bronchoscopy represent critical aspect, however, other consideration has to be pondered.", [["personal Protective Equipment (PPE)", "TREATMENT", 11, 46], ["HEPA filter", "TREATMENT", 48, 59], ["closed line suction", "TREATMENT", 61, 80], ["non-fenestrated cuffed cannula", "TREATMENT", 82, 112], ["sealed port", "TREATMENT", 117, 128], ["bronchoscopy", "TREATMENT", 133, 145], ["HEPA filter", "OBSERVATION", 48, 59], ["line suction", "OBSERVATION", 68, 80], ["cuffed cannula", "OBSERVATION", 98, 112]]], ["No evidence is now available regarding the different impact of open surgical tracheostomy versus percutaneous dilation tracheostomy in terms of aerosol generation, consequently, local expertise, resources and patients' characteristics should guide the choice between the two techniques [11] .", [["percutaneous", "ANATOMY", 97, 109], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["open surgical tracheostomy", "TREATMENT", 63, 89], ["percutaneous dilation tracheostomy", "TREATMENT", 97, 131], ["aerosol generation", "TREATMENT", 144, 162], ["surgical tracheostomy", "OBSERVATION", 68, 89], ["dilation", "OBSERVATION_MODIFIER", 110, 118], ["tracheostomy", "OBSERVATION", 119, 131], ["aerosol generation", "OBSERVATION", 144, 162]]], ["Similarly, the choice of the optimal location to perform tracheostomy has to follow the same criteria.", [["tracheostomy", "TREATMENT", 57, 69], ["tracheostomy", "OBSERVATION", 57, 69]]], ["Tracheostomy should be performed in a negative pressure room, preferably in an isolated room of ICU in order to reduce transportation and consequent lower contamination risk.", [["Tracheostomy", "TREATMENT", 0, 12], ["consequent lower contamination risk", "PROBLEM", 138, 173], ["lower contamination", "OBSERVATION_MODIFIER", 149, 168]]], ["Another critical point is represented by the creation of a dedicated airway team.", [["airway", "ANATOMY", 69, 75], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["airway", "ANATOMY", 69, 75]]], ["In fact, important aspects for reducing aerosol generation and increase safety are represented by effective communication and coordinated teamwork between the intensivists, surgeon and nurse; consequently, the institution of an \"Airway-team\" should be considered in any hospital.", [["Airway", "MULTI-TISSUE_STRUCTURE", 229, 235], ["reducing aerosol generation", "TREATMENT", 31, 58], ["Airway", "ANATOMY", 229, 235]]], ["During the procedure, particular attention has to be put on several technical aspects:Dear Editor,\u2022 Be sure that the patient is stable enough to tolerate apnoeic time and supine position, otherwise, reconsider timing of the procedure; \u2022 Preoxygenation-peroxygenation; \u2022 Ascertain a proper hypnosis and paralysis in order to avoid movement and cough; \u2022 Avoid inappropriate ventilation circuit disconnection; \u2022 Clamp the tube and stop the ventilation any time there is the need of open the circuit/deflate the cuff/reposition of the tube/tracheal incision/creation of tracheal window; \u2022 Decontamination.Dear Editor,During post-procedural phase, consider periodic cuff control of the cannula with a manometer in order to reduce the incidence of tracheal lesion.", [["tube", "ANATOMY", 419, 423], ["cuff", "ANATOMY", 508, 512], ["tube", "ANATOMY", 531, 535], ["tracheal", "ANATOMY", 536, 544], ["tracheal", "ANATOMY", 566, 574], ["tracheal lesion", "ANATOMY", 742, 757], ["paralysis", "DISEASE", 302, 311], ["cough", "DISEASE", 343, 348], ["tracheal lesion", "DISEASE", 742, 757], ["patient", "ORGANISM", 117, 124], ["tube", "TISSUE", 419, 423], ["tube", "TISSUE", 531, 535], ["tracheal", "ORGAN", 536, 544], ["tracheal", "ORGAN", 566, 574], ["tracheal lesion", "PATHOLOGICAL_FORMATION", 742, 757], ["patient", "SPECIES", 117, 124], ["the procedure", "TREATMENT", 7, 20], ["the procedure", "TREATMENT", 220, 233], ["Preoxygenation", "TREATMENT", 237, 251], ["a proper hypnosis", "PROBLEM", 280, 297], ["paralysis", "PROBLEM", 302, 311], ["cough", "PROBLEM", 343, 348], ["inappropriate ventilation circuit disconnection", "TREATMENT", 358, 405], ["Clamp the tube", "TREATMENT", 409, 423], ["the ventilation", "TREATMENT", 433, 448], ["open the circuit", "TREATMENT", 479, 495], ["the cuff", "TREATMENT", 504, 512], ["reposition", "TREATMENT", 513, 523], ["the tube", "TREATMENT", 527, 535], ["tracheal incision", "TREATMENT", 536, 553], ["tracheal window", "TREATMENT", 566, 581], ["Decontamination", "TREATMENT", 585, 600], ["periodic cuff control", "TREATMENT", 652, 673], ["the cannula", "TREATMENT", 677, 688], ["a manometer", "TREATMENT", 694, 705], ["tracheal lesion", "PROBLEM", 742, 757], ["hypnosis", "OBSERVATION", 289, 297], ["paralysis", "OBSERVATION", 302, 311], ["tube", "OBSERVATION", 419, 423], ["cuff", "ANATOMY", 508, 512], ["tube", "OBSERVATION", 531, 535], ["tracheal", "ANATOMY", 536, 544], ["incision", "OBSERVATION", 545, 553], ["tracheal window", "ANATOMY", 566, 581], ["tracheal", "ANATOMY", 742, 750], ["lesion", "OBSERVATION", 751, 757]]], ["Even more, consider deflating the cuff and use fenestrated cannula only when the patient is considered COVID negative.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["the cuff", "TREATMENT", 30, 38], ["fenestrated cannula", "TREATMENT", 47, 66], ["cuff", "OBSERVATION", 34, 38]]], ["A checklist for the evaluation of all these critical aspects is proposed in Table 1 .Dear Editor,In conclusion, this pandemic represents a clinical and organizational crisis.", [["the evaluation", "TEST", 16, 30], ["a clinical and organizational crisis", "PROBLEM", 137, 173], ["organizational crisis", "OBSERVATION", 152, 173]]], ["Not to be underestimated, in addition to the high requirement of intensivists working on COVID positive patients, intensivists continue also to manage the general emergency call.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Consequently, we strongly believe that any procedure or medical strategy that help clinicians in facilitating the general clinical course of COVID patients have to be followed.", [["COVID", "DISEASE", 141, 146], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["any procedure", "TREATMENT", 39, 52], ["medical strategy", "TREATMENT", 56, 72], ["COVID patients", "TREATMENT", 141, 155]]], ["In this light, early tracheostomy and the creation of sub-intensive and respiratory intensive care units can play an important role not to be underestimated.Dear Editor,Funding None.Compliance with ethical standardsConflict of interest The authors declare that they have no competing interests.Statements on human and animal rightsThis article does not contain any studies with human participants or animals performed by any of the authors.Statements on human and animal rightsInformed consent None.", [["human", "ORGANISM", 308, 313], ["human", "ORGANISM", 378, 383], ["human", "ORGANISM", 454, 459], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 378, 383], ["participants", "SPECIES", 384, 396], ["human", "SPECIES", 454, 459], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 454, 459], ["early tracheostomy", "TREATMENT", 15, 33], ["respiratory intensive care units", "TREATMENT", 72, 104], ["ethical standards", "TREATMENT", 198, 215], ["early", "OBSERVATION_MODIFIER", 15, 20], ["tracheostomy", "OBSERVATION", 21, 33], ["sub", "OBSERVATION_MODIFIER", 54, 57]]]], "PMC7448928": [["To date, COVID-19 continues to be a challenge to global public health.", [["COVID-19", "CHEMICAL", 9, 17], ["COVID", "TEST", 9, 14]]], ["The newly emerging SARS-related coronavirus designated as SARS-CoV-2 is the third highly pathogenic Betacoronavirus to infect human populations in the twenty-first century [1].", [["SARS-related coronavirus", "DISEASE", 19, 43], ["SARS", "DISEASE", 58, 62], ["SARS-related coronavirus", "ORGANISM", 19, 43], ["SARS-CoV-2", "ORGANISM", 58, 68], ["Betacoronavirus", "ORGANISM", 100, 115], ["human", "ORGANISM", 126, 131], ["coronavirus", "SPECIES", 32, 43], ["human", "SPECIES", 126, 131], ["SARS-CoV-2", "SPECIES", 58, 68], ["human", "SPECIES", 126, 131], ["The newly emerging SARS", "PROBLEM", 0, 23], ["related coronavirus", "PROBLEM", 24, 43], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66]]], ["SARS-CoV-2 emerged in Wuhan, China in late December 2019 and has spread to more than 210 countries in every continent on earth except Antarctica.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10]]], ["COVID-19 is the first pandemic in history to be caused by a coronavirus.", [["COVID-19", "CHEMICAL", 0, 8], ["coronavirus", "DISEASE", 60, 71], ["coronavirus", "ORGANISM", 60, 71], ["COVID", "TEST", 0, 5], ["a coronavirus", "PROBLEM", 58, 71], ["coronavirus", "OBSERVATION", 60, 71]]], ["While the huge negative effects of living through the COVID-19 pandemic are obvious \u2013 psychological stress, fear, severe global economic losses, overwhelmed health care systems and general disruption of societies \u2013 the ongoing pandemic may also have some indirect positive impacts.", [["psychological stress", "PROBLEM", 86, 106], ["severe global economic losses", "PROBLEM", 114, 143], ["general disruption of societies", "PROBLEM", 181, 212], ["huge", "OBSERVATION_MODIFIER", 10, 14], ["negative", "OBSERVATION", 15, 23], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["global", "OBSERVATION_MODIFIER", 121, 127], ["economic losses", "OBSERVATION", 128, 143]]], ["Virus outbreaks often have large negative impacts on human health [2] but changes in our way of life due to outbreak responses may serve as demonstrations of possible positive changes for the environment, health of humans, animals and the ecosystem.", [["human", "ORGANISM", 53, 58], ["humans", "ORGANISM", 215, 221], ["human", "SPECIES", 53, 58], ["humans", "SPECIES", 215, 221], ["human", "SPECIES", 53, 58], ["humans", "SPECIES", 215, 221], ["Virus outbreaks", "PROBLEM", 0, 15], ["positive changes", "PROBLEM", 167, 183], ["large", "OBSERVATION_MODIFIER", 27, 32], ["negative", "OBSERVATION", 33, 41], ["impacts", "OBSERVATION_MODIFIER", 42, 49]]]], "PMC7456442": [], "PMC7435101": [["It has been widely used in various fields, including healthcare, where it has helped in training, understanding, and implementing skillsets in order to improve patient care and outcome.1\u20134 An ideal simulation model should be good enough to demonstrate realistic clinical scenarios and respond to interventions done by trainees in real time.BACKGROUNDIn intensive care units (ICU), effective management of the critically ill is a difficult task and involves assimilation and integration of large volumes of information, critical thinking and correct decision-making.2,4 In ICU, simulators are used in teaching cardiopulmonary resuscitation, difficult airway management and teaching skills like intravascular access.5\u20137 The use of simulation in teaching advanced ventilatory and hemodynamic scenarios has not been well described.BACKGROUNDThe aim of our study was to prospectively evaluate the effectiveness of simulation model \u201cCRITICA\u201d\u2122 (MEDUPLAY systems) in training critical care physicians.", [["airway", "ANATOMY", 650, 656], ["intravascular", "ANATOMY", 693, 706], ["1\u20134", "CHEMICAL", 185, 188], ["critically ill", "DISEASE", 409, 423], ["5\u20137", "CHEMICAL", 714, 717], ["patient", "ORGANISM", 160, 167], ["airway", "MULTI-TISSUE_STRUCTURE", 650, 656], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 693, 706], ["patient", "SPECIES", 160, 167], ["interventions", "TREATMENT", 296, 309], ["effective management", "TREATMENT", 381, 401], ["cardiopulmonary resuscitation", "TREATMENT", 609, 638], ["difficult airway management", "TREATMENT", 640, 667], ["teaching skills", "TREATMENT", 672, 687], ["intravascular access", "TREATMENT", 693, 713], ["simulation in teaching advanced ventilatory", "TREATMENT", 729, 772], ["our study", "TEST", 848, 857], ["widely", "OBSERVATION_MODIFIER", 12, 18], ["hemodynamic scenarios", "OBSERVATION", 777, 798]]], ["Secondary objective was to evaluate usefulness of the workshop as assessed by \u201cLikert scale\u201d.MATERIALS AND METHODSThe advanced ICU simulator \u201cCRITICA\u201d\u2122 (MEDUPLAY systems) was developed as a joint collaboration with the Indian Institute of Science and St. John\u2019s Medical College in the year 2015.", [["CRITICA\u201d\u2122 (MEDUPLAY systems", "TREATMENT", 142, 169], ["joint", "ANATOMY", 190, 195]]], ["It is a complex macrosimulator.", [["complex", "OBSERVATION_MODIFIER", 8, 15], ["macrosimulator", "OBSERVATION", 16, 30]]], ["While designing the simulator, each feature of the simulator was tested among ICU trainees, and based on the feedback given, necessary modifications were done.MATERIALS AND METHODSThe simulator used in this study consists of a mannequin which is intubatable and simulates clinically examinable respiratory and cardiac functionality.", [["respiratory", "ANATOMY", 294, 305], ["cardiac", "ANATOMY", 310, 317], ["cardiac", "ORGAN", 310, 317], ["this study", "TEST", 202, 212], ["a mannequin", "TREATMENT", 225, 236], ["cardiac", "ANATOMY", 310, 317]]], ["In addition, there are two screens (Figs 1 and 2).", [["two screens", "TEST", 23, 34], ["Figs", "TEST", 36, 40]]], ["One screen displays electrocardiogram (ECG), pulse oximetry, end tidal CO2 (ETCO2), noninvasive blood pressure (NIBP), arterial blood pressure, and cardiac output (Fig. 1).", [["blood", "ANATOMY", 96, 101], ["arterial", "ANATOMY", 119, 127], ["blood", "ANATOMY", 128, 133], ["cardiac", "ANATOMY", 148, 155], ["CO2", "CHEMICAL", 71, 74], ["CO2", "CHEMICAL", 71, 74], ["CO2", "SIMPLE_CHEMICAL", 71, 74], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 119, 133], ["cardiac", "ORGAN", 148, 155], ["One screen", "TEST", 0, 10], ["electrocardiogram", "TEST", 20, 37], ["ECG", "TEST", 39, 42], ["pulse oximetry", "TEST", 45, 59], ["end tidal CO2", "TEST", 61, 74], ["ETCO2", "TEST", 76, 81], ["noninvasive blood pressure", "TEST", 84, 110], ["NIBP", "TEST", 112, 116], ["arterial blood pressure", "TEST", 119, 142], ["cardiac output", "TEST", 148, 162], ["pressure", "OBSERVATION_MODIFIER", 134, 142], ["cardiac", "ANATOMY", 148, 155], ["output", "OBSERVATION_MODIFIER", 156, 162]]], ["Additional functionalities like assessment of fluid responsiveness by systolic pressure variation, pulse pressure variation and demonstration of passive leg raising are also possible.", [["fluid", "ANATOMY", 46, 51], ["leg", "ANATOMY", 153, 156], ["leg", "ORGANISM_SUBDIVISION", 153, 156], ["assessment of fluid responsiveness", "TEST", 32, 66], ["systolic pressure variation", "TEST", 70, 97], ["pulse pressure variation", "TEST", 99, 123], ["passive leg raising", "PROBLEM", 145, 164], ["fluid responsiveness", "OBSERVATION", 46, 66], ["leg", "ANATOMY", 153, 156]]], ["The effect of drugs and pathological conditions on arterial wave morphology can be easily simulated.MATERIALS AND METHODSThe second screen replicates and simulates the outputs of a modern ICU ventilator and displays ventilator scalars, loops, different ventilator parameters and alarms settings (Fig. 2).", [["arterial", "ANATOMY", 51, 59], ["arterial", "MULTI-TISSUE_STRUCTURE", 51, 59], ["drugs", "TREATMENT", 14, 19], ["pathological conditions", "PROBLEM", 24, 47], ["arterial wave morphology", "TEST", 51, 75], ["METHODSThe second screen", "TEST", 114, 138], ["a modern ICU ventilator", "TREATMENT", 179, 202], ["ventilator scalars", "TREATMENT", 216, 234], ["different ventilator parameters", "TREATMENT", 243, 274], ["alarms settings", "TREATMENT", 279, 294], ["ventilator scalars", "OBSERVATION", 216, 234], ["loops", "OBSERVATION_MODIFIER", 236, 241]]], ["Different modes like pressure control, volume control, pressure-regulated volume control, and pressure support can be simulated.", [["pressure control", "TREATMENT", 21, 37], ["volume control", "TREATMENT", 39, 53], ["pressure-regulated volume control", "TREATMENT", 55, 88], ["pressure support", "TREATMENT", 94, 110], ["pressure", "OBSERVATION_MODIFIER", 21, 29]]], ["The resistance and compliance of the simulated respiratory system are fully controllable by the trainer and changes made in these parameters are reflected in the loops and the scalars with high fidelity.MATERIALS AND METHODSThis simulator has been extensively and exclusively used in our institutional workshops for critical care trainees from 2015 to 2018.", [["resistance", "OBSERVATION", 4, 14], ["compliance", "OBSERVATION_MODIFIER", 19, 29], ["respiratory system", "ANATOMY", 47, 65], ["loops", "OBSERVATION", 162, 167], ["high fidelity", "OBSERVATION", 189, 202]]], ["Total six workshops were conducted during this period.", [["Total six workshops", "TREATMENT", 0, 19]]], ["Pre- and posttest scores were available for five workshops.", [["posttest scores", "TEST", 9, 24]]], ["Before the workshop, teaching material was emailed to the registered participants.", [["participants", "SPECIES", 69, 81], ["teaching material", "TREATMENT", 21, 38]]], ["On day 1, mechanical ventilation was taught, and on day 2, hemodynamic monitoring was taught.", [["mechanical ventilation", "TREATMENT", 10, 32], ["hemodynamic monitoring", "TEST", 59, 81], ["mechanical ventilation", "OBSERVATION", 10, 32]]], ["Intensive didactic and case-based scenarios were simulated to formally teach principles of advanced ICU scenarios.", [["advanced ICU scenarios", "TREATMENT", 91, 113]]], ["Trainee\u2019s performance was tested by pretest and posttest scores.", [["posttest scores", "TEST", 48, 63]]], ["Pretest followed by posttest was conducted on day 1 and day 2 for the respective modules.MATERIALS AND METHODSThe questionnaire in mechanical ventilation included pattern recognition and clinical reasoning (Appendix: Supplementary material, Fig. A1).", [["A1", "GENE_OR_GENE_PRODUCT", 246, 248], ["A1", "PROTEIN", 246, 248], ["mechanical ventilation", "TREATMENT", 131, 153], ["mechanical ventilation", "OBSERVATION", 131, 153], ["Appendix", "ANATOMY", 207, 215]]], ["The scenarios in mechanical ventilation included identification of mode of ventilation, clinical reasoning for the same, phase variables, identifying compliance or resistance issues as in acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD) respectively, and it also included aspects of changing mode from volume to pressure control.", [["respiratory", "ANATOMY", 194, 205], ["pulmonary", "ANATOMY", 255, 264], ["acute respiratory distress syndrome", "DISEASE", 188, 223], ["ARDS", "DISEASE", 225, 229], ["chronic obstructive pulmonary disease", "DISEASE", 235, 272], ["COPD", "DISEASE", 274, 278], ["pulmonary", "ORGAN", 255, 264], ["mechanical ventilation", "TREATMENT", 17, 39], ["ventilation", "TREATMENT", 75, 86], ["resistance issues", "PROBLEM", 164, 181], ["acute respiratory distress syndrome", "PROBLEM", 188, 223], ["ARDS", "PROBLEM", 225, 229], ["chronic obstructive pulmonary disease", "PROBLEM", 235, 272], ["COPD", "PROBLEM", 274, 278], ["volume to pressure control", "TREATMENT", 345, 371], ["mechanical ventilation", "OBSERVATION", 17, 39], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["respiratory distress", "OBSERVATION", 194, 214], ["chronic", "OBSERVATION_MODIFIER", 235, 242], ["obstructive", "OBSERVATION_MODIFIER", 243, 254], ["pulmonary", "ANATOMY", 255, 264], ["disease", "OBSERVATION", 265, 272], ["COPD", "OBSERVATION", 274, 278]]], ["For hemodynamic monitoring, the questionnaire comprised of complex integration of the available information and testing the skills on critical thinking and decision-making (Appendix: Supplementary material, Fig. A2).", [["A2", "GENE_OR_GENE_PRODUCT", 212, 214], ["A2", "PROTEIN", 212, 214], ["hemodynamic monitoring", "TEST", 4, 26], ["Appendix", "ANATOMY", 173, 181]]], ["It included fluid assessment, arterial blood gas (ABG) analysis, ultrasonography (USG), echocardiographic evaluation and designing the management plan.", [["fluid", "ANATOMY", 12, 17], ["arterial blood", "ANATOMY", 30, 44], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 30, 44], ["fluid assessment", "TEST", 12, 28], ["arterial blood gas", "TEST", 30, 48], ["ABG) analysis", "TEST", 50, 63], ["ultrasonography", "TEST", 65, 80], ["USG", "TEST", 82, 85], ["echocardiographic evaluation", "TEST", 88, 116], ["the management plan", "TREATMENT", 131, 150], ["fluid", "OBSERVATION", 12, 17]]], ["Total score out of 10 was calculated.MATERIALS AND METHODSStatistical analysis was done using Stata v14\u2122 (College station, TX).", [["Total score", "TEST", 0, 11], ["METHODSStatistical analysis", "TEST", 51, 78]]], ["Paired \u201ct\u201d test was used for parametric data and \u201cWilcoxon signed rank\u201d test was used for nonparametric data.", [["Paired \u201ct\u201d test", "TEST", 0, 15], ["parametric data", "TEST", 29, 44], ["nonparametric data", "TEST", 90, 108]]], ["Effect of specialty and designation on change in scores was evaluated by ANOVA (analysis of variance).", [["change in scores", "PROBLEM", 39, 55]]], ["At the end of workshop, feedback form consisting of five questionnaire was given and response was evaluated based on \u201cLikert scale\u201d (Appendix: Supplementary digital content, Table A1).RESULTSA total of 143 participants were evaluated.", [["participants", "ORGANISM", 206, 218], ["participants", "SPECIES", 206, 218], ["Appendix", "ANATOMY", 133, 141]]], ["The presimulation test scores and postsimulation test scores were calculated.", [["The presimulation test scores", "TEST", 0, 29], ["postsimulation test scores", "TEST", 34, 60]]], ["Participants underwent 2 days workshop for hemodynamic monitoring and mechanical ventilation.", [["Participants", "SPECIES", 0, 12], ["hemodynamic monitoring", "TEST", 43, 65], ["mechanical ventilation", "TREATMENT", 70, 92], ["mechanical ventilation", "OBSERVATION", 70, 92]]], ["Only participants who had both pre- and posttest results were included in analysis.", [["participants", "ORGANISM", 5, 17], ["participants", "SPECIES", 5, 17]]], ["Paired data were available for 75 participants for hemodynamic monitoring and 71 for mechanical ventilation.", [["participants", "SPECIES", 34, 46], ["Paired data", "TEST", 0, 11], ["hemodynamic monitoring", "TEST", 51, 73], ["mechanical ventilation", "TREATMENT", 85, 107], ["mechanical ventilation", "OBSERVATION", 85, 107]]], ["Pre- and posttest scores for both the modules were calculated.", [["posttest scores", "TEST", 9, 24]]], ["Posttest scores were higher for both the modules and were statistically significant (Table 1).", [["Posttest scores", "TEST", 0, 15]]], ["Mechanical ventilation module posttest score was higher than the hemodynamic monitoring module.", [["Mechanical ventilation module posttest score", "TEST", 0, 44]]], ["The analysis based on types of questionnaire, such as, pattern recognition or analytical thinking, posttest scores were higher and statistically significant as shown in Table 1.", [["The analysis", "TEST", 0, 12], ["posttest scores", "TEST", 99, 114]]], ["The feedback by trainees has been displayed using a Likert scale (Fig. 3).", [["a Likert scale", "TREATMENT", 50, 64]]], ["There was no effect of specialty and designation on difference between pre- and posttest scores in mechanical ventilation module, [F(2,1) 0.67, p = 0.51] and in hemodynamic monitoring module [F(2,1) 1.45, p = 0.24] (Appendix: Supplementary digital content, Tables A2 and A3).", [["posttest scores", "TEST", 80, 95], ["mechanical ventilation module", "TREATMENT", 99, 128], ["hemodynamic monitoring module", "TEST", 161, 190], ["p", "TEST", 205, 206], ["no", "UNCERTAINTY", 10, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["mechanical ventilation", "OBSERVATION", 99, 121], ["Appendix", "ANATOMY", 216, 224]]], ["There was no effect of specialty on difference between pre- and posttest scores in pattern recognition questionnaire [F(2,1) 0.37, p = 0.69] and in analytical thinking questionnaire [F(2,1) 0.72, p = 0.48] (Appendix: Supplementary digital content, Tables A4 and A5).DISCUSSIONThe present ICU simulator has shown that teaching of advanced ventilator and hemodynamic monitoring is possible.", [["p", "TEST", 196, 197], ["Supplementary digital content", "TEST", 217, 246], ["advanced ventilator", "TREATMENT", 329, 348], ["hemodynamic monitoring", "TEST", 353, 375], ["no", "UNCERTAINTY", 10, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["Appendix", "ANATOMY", 207, 215]]], ["It has helped the trainees in understanding the principles of mechanical ventilation and hemodynamic monitoring as shown by posttest scores.", [["mechanical ventilation", "TREATMENT", 62, 84], ["hemodynamic monitoring", "TEST", 89, 111], ["mechanical ventilation", "OBSERVATION", 62, 84]]], ["There was no effect of specialty and designation on scores of trainees, possible reason being, this method of teaching was new and there was no prior experience of simulator-based training in the cohort evaluated in this study.DISCUSSIONVarious studies have used static simulation for teaching cardiopulmonary resuscitation, difficult airway management, ECG, and echocardiography.5,6,8 These studies found that simulation-based learning was effective.", [["cardiopulmonary", "ANATOMY", 294, 309], ["airway", "ANATOMY", 335, 341], ["5,6,8", "CHEMICAL", 380, 385], ["airway", "MULTI-TISSUE_STRUCTURE", 335, 341], ["5,6,8", "SIMPLE_CHEMICAL", 380, 385], ["simulator-based training", "TREATMENT", 164, 188], ["this study", "TEST", 216, 226], ["static simulation", "TEST", 263, 280], ["teaching cardiopulmonary resuscitation", "TREATMENT", 285, 323], ["difficult airway management", "TREATMENT", 325, 352], ["ECG", "TEST", 354, 357], ["echocardiography", "TEST", 363, 379], ["These studies", "TEST", 386, 399], ["no", "UNCERTAINTY", 10, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19]]], ["It was also found to be useful in identification of medication-related errors.9DISCUSSIONSimulation of mechanical ventilation was used in one study.", [["medication", "TREATMENT", 52, 62], ["mechanical ventilation", "TREATMENT", 103, 125], ["one study", "TEST", 138, 147], ["mechanical ventilation", "OBSERVATION", 103, 125]]], ["This was a comparison between computer-based and mannequin-based learning and it showed that mannequin-based learning has the advantage of improving skills in managing mechanical ventilation.10 In pediatric population, simulation of ARDS ventilation was found to be useful in improving time to effective interventions and behavioral skills.11 Similar study was done in pediatric population using the embedded simulation training program, which involved three phases of training and study was done over a period of 2 years.", [["ARDS", "DISEASE", 233, 237], ["mannequin", "TREATMENT", 49, 58], ["mannequin", "TREATMENT", 93, 102], ["managing mechanical ventilation", "TREATMENT", 159, 190], ["ARDS ventilation", "TREATMENT", 233, 249], ["effective interventions", "TREATMENT", 294, 317], ["behavioral skills", "TEST", 322, 339], ["Similar study", "TEST", 343, 356], ["the embedded simulation training program", "TREATMENT", 396, 436], ["study", "TEST", 482, 487], ["mechanical ventilation", "OBSERVATION", 168, 190], ["ARDS ventilation", "OBSERVATION", 233, 249]]], ["This study showed 6\u201312 months of learning curve in implementation of training program.", [["This study", "TEST", 0, 10], ["training program", "TREATMENT", 69, 85]]], ["Repeated exposure to simulation is more beneficial than single exposure.", [["more beneficial", "OBSERVATION_MODIFIER", 35, 50]]], ["This is in contrary to our study in which only a single assessment was done and our study did not look at long-term impact of simulator-based training.12DISCUSSIONA meta-analysis comprising of 17 studies testing the use of simulator in various acute care settings, such as, emergency, trauma, operation room and ICU showed feasibility of simulation-based training in acute care settings, but there is lack of evidence on its effect on patient outcome.13DISCUSSIONAs compared to previous studies, this simulator is a high fidelity model and one can simulate any scenario by altering resistance and compliance of the respiratory system.", [["trauma", "DISEASE", 285, 291], ["patient", "ORGANISM", 435, 442], ["patient", "SPECIES", 435, 442], ["our study", "TEST", 23, 32], ["a single assessment", "TEST", 47, 66], ["our study", "TEST", 80, 89], ["17 studies", "TEST", 193, 203], ["acute care settings", "TREATMENT", 367, 386], ["previous studies", "TEST", 478, 494], ["altering resistance and compliance of the respiratory system", "PROBLEM", 573, 633], ["high fidelity", "OBSERVATION_MODIFIER", 516, 529], ["respiratory system", "ANATOMY", 615, 633]]], ["In the hemodynamic monitoring module, various types of shocks can be simulated.", [["shocks", "TREATMENT", 55, 61]]], ["Previous studies have shown that teaching a particular task, such as, echocardiography, extracorporeal membrane oxygenation (ECMO), pneumonia, palliative care, ARDS and cardiac surgery by using simulator is possible.14\u201319 The advantage of the current simulation model is a single simulation model, which can help to understand cardiorespiratory pathophysiology and any cardiorespiratory derangement can be simulated but present simulator does not have difficult airway management module.DISCUSSIONOur study has certain limitations.", [["extracorporeal membrane", "ANATOMY", 88, 111], ["cardiac", "ANATOMY", 169, 176], ["airway", "ANATOMY", 462, 468], ["pneumonia", "DISEASE", 132, 141], ["ARDS", "DISEASE", 160, 164], ["cardiorespiratory derangement", "DISEASE", 369, 398], ["cardiac", "ORGAN", 169, 176], ["airway", "MULTI-TISSUE_STRUCTURE", 462, 468], ["Previous studies", "TEST", 0, 16], ["echocardiography", "TEST", 70, 86], ["extracorporeal membrane oxygenation", "TREATMENT", 88, 123], ["ECMO", "TREATMENT", 125, 129], ["pneumonia", "PROBLEM", 132, 141], ["palliative care", "TREATMENT", 143, 158], ["ARDS", "PROBLEM", 160, 164], ["cardiac surgery", "TREATMENT", 169, 184], ["a single simulation model", "TREATMENT", 271, 296], ["any cardiorespiratory derangement", "PROBLEM", 365, 398], ["difficult airway management module", "PROBLEM", 452, 486], ["DISCUSSIONOur study", "TEST", 487, 506], ["pneumonia", "OBSERVATION", 132, 141]]], ["It was a single-center study.", [["a single-center study", "TEST", 7, 28]]], ["The trainee\u2019s performance was tested after 2 days of training and it showed improvement in the performance.", [["training", "TREATMENT", 53, 61], ["improvement", "OBSERVATION_MODIFIER", 76, 87]]], ["In practice, based on one clinical assessment, it is difficult to find out if trainee has achieved adequate level of competence in dealing with the complex real-life critical care scenarios.", [["one clinical assessment", "TEST", 22, 45]]], ["It was a 2-day workshop training and the majority of participants who attended were not from same institute; hence, repeat assessment of the trainee\u2019s performance was not possible.", [["participants", "ORGANISM", 53, 65], ["participants", "SPECIES", 53, 65], ["repeat assessment", "TEST", 116, 133]]], ["As compared to previous studies, effect of stress and anxiety level was not tested and behavioral skills were not evaluated.12,20 We could not compare simulator-based training with classical method of training.CONCLUSIONPresent simulation model has shown to be beneficial in teaching advanced mechanical ventilation and hemodynamic monitoring to critical care physicians.", [["anxiety", "DISEASE", 54, 61], ["previous studies", "TEST", 15, 31], ["stress and anxiety level", "PROBLEM", 43, 67], ["behavioral skills", "TEST", 87, 104], ["classical method of training", "TREATMENT", 181, 209], ["mechanical ventilation", "TREATMENT", 293, 315], ["hemodynamic monitoring", "TEST", 320, 342]]], ["Considering the complexity in managing critically ill patients as compared to other routine modalities of training, advantage of simulation-based training is that there is no harm to patients during training.", [["critically ill", "DISEASE", 39, 53], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 183, 191], ["routine modalities of training", "TREATMENT", 84, 114], ["simulation-based training", "TREATMENT", 129, 154], ["no", "UNCERTAINTY", 172, 174]]], ["Comparison of routine classroom teaching and simulator-based training needs to be evaluated prospectively.TAKE HOME MESSAGESimulator-based training in hemodynamic monitoring and mechanical ventilation is effective and it may help the trainees to learn different aspects of hemodynamic monitoring and mechanical ventilation without causing any harm to the patientAVAILABILITY OF DATA AND MATERIALSThe datasets used and analyzed in the present study are available from the corresponding author upon request.AUTHOR\u2019S CONTRIBUTIONAmarja Ashok Havaldar helped in designing the study, designing questionnaire data collection, analysis, and drafted the manuscript.", [["patient", "ORGANISM", 355, 362], ["patient", "SPECIES", 355, 362], ["routine classroom teaching", "TREATMENT", 14, 40], ["simulator-based training", "TREATMENT", 45, 69], ["HOME MESSAGESimulator", "TREATMENT", 111, 132], ["hemodynamic monitoring", "TEST", 151, 173], ["mechanical ventilation", "TREATMENT", 178, 200], ["hemodynamic monitoring", "TEST", 273, 295], ["mechanical ventilation", "TREATMENT", 300, 322], ["the present study", "TEST", 430, 447], ["the study", "TEST", 568, 577], ["questionnaire data collection", "TEST", 589, 618], ["analysis", "TEST", 620, 628]]], ["Bhuvana Krishna helped in drafting the manuscript, Sriram Sampath helped in statistical analysis and drafting the manuscript, and Sarvana Kumar Paramasivam helped in designing questionnaire", [["Bhuvana", "TREATMENT", 0, 7], ["Sriram Sampath", "TREATMENT", 51, 65], ["Sarvana", "TREATMENT", 130, 137]]]], "PMC7112994": [["INTRODUCTIONSeasonal influenza disease causes substantial morbidity in the United States \u2013 200 000 annual hospitalizations, thousands of annual deaths [1], and many emergency department (ED) and outpatient visits [2\u20134].", [["influenza disease", "DISEASE", 21, 38], ["deaths", "DISEASE", 144, 150], ["INTRODUCTIONSeasonal influenza disease", "PROBLEM", 0, 38], ["substantial", "OBSERVATION_MODIFIER", 46, 57], ["morbidity", "OBSERVATION", 58, 67]]], ["Most recent studies of the burden of influenza disease have focused on healthcare visits; few have examined the community-wide burden of influenza in the general population [5, 6].", [["influenza disease", "DISEASE", 37, 54], ["influenza", "DISEASE", 137, 146], ["influenza disease", "PROBLEM", 37, 54], ["influenza", "PROBLEM", 137, 146], ["influenza", "OBSERVATION", 37, 46], ["influenza", "OBSERVATION", 137, 146]]], ["Because many individuals with influenza disease do not seek medical care but are nevertheless ill enough to miss work or school [7\u201312], the high morbidity documented in studies of influenza-related illness may underestimate the burden of influenza.", [["influenza disease", "DISEASE", 30, 47], ["influenza", "DISEASE", 180, 189], ["illness", "DISEASE", 198, 205], ["influenza", "DISEASE", 238, 247], ["influenza disease", "PROBLEM", 30, 47], ["the high morbidity", "PROBLEM", 136, 154], ["influenza", "PROBLEM", 180, 189], ["influenza", "PROBLEM", 238, 247], ["influenza", "OBSERVATION", 238, 247]]], ["With vaccination coverage hovering at only 50% (43% in the 2010\u20132011 season, http://www.cdc.gov/flu/fluvaxview/coverage_1011estimates.htm) [13] despite universal vaccination recommendations [14], it is important to understand the full impact of this virus at the population level.INTRODUCTIONOther viruses also cause acute respiratory illnesses (ARIs) and it is important to document their population-wide impact.", [["respiratory", "ANATOMY", 323, 334], ["acute respiratory illnesses", "DISEASE", 317, 344], ["ARIs", "DISEASE", 346, 350], ["vaccination coverage", "TREATMENT", 5, 25], ["universal vaccination recommendations", "TREATMENT", 152, 189], ["this virus", "PROBLEM", 245, 255], ["acute respiratory illnesses (ARIs)", "PROBLEM", 317, 351], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["respiratory", "ANATOMY", 323, 334], ["illnesses", "OBSERVATION", 335, 344]]], ["A Healthy People 2020 goal is to prevent disease, disability, and death from infectious disease.", [["disability", "DISEASE", 50, 60], ["death", "DISEASE", 66, 71], ["infectious disease", "DISEASE", 77, 95], ["People", "SPECIES", 10, 16], ["disease", "PROBLEM", 41, 48], ["death", "PROBLEM", 66, 71], ["infectious disease", "PROBLEM", 77, 95], ["infectious", "OBSERVATION", 77, 87]]], ["Population-level surveillance is an integral step in assessing morbidity from ARIs.", [["ARIs", "DISEASE", 78, 82], ["an integral step", "TEST", 33, 49], ["ARIs", "PROBLEM", 78, 82]]], ["Also vaccines are in development for several viral pathogens including respiratory syncytial virus (RSV) [15], parainfluenza viruses (PIVs) [16], and human metapneumovirus (hMPV, first identified in the early 2000s) which are significant causes of hospitalizations, ED visits and outpatient visits [2, 17\u201319].", [["respiratory syncytial virus (RSV)", "DISEASE", 71, 104], ["parainfluenza viruses", "DISEASE", 111, 132], ["human metapneumovirus", "DISEASE", 150, 171], ["hMPV", "DISEASE", 173, 177], ["respiratory syncytial virus", "ORGANISM", 71, 98], ["RSV", "ORGANISM", 100, 103], ["parainfluenza viruses", "ORGANISM", 111, 132], ["human", "ORGANISM", 150, 155], ["metapneumovirus", "ORGANISM", 156, 171], ["hMPV", "ORGANISM", 173, 177], ["respiratory syncytial virus", "SPECIES", 71, 98], ["parainfluenza", "SPECIES", 111, 124], ["human", "SPECIES", 150, 155], ["metapneumovirus", "SPECIES", 156, 171], ["respiratory syncytial virus", "SPECIES", 71, 98], ["RSV", "SPECIES", 100, 103], ["human metapneumovirus", "SPECIES", 150, 171], ["hMPV", "SPECIES", 173, 177], ["vaccines", "TREATMENT", 5, 13], ["several viral pathogens", "PROBLEM", 37, 60], ["respiratory syncytial virus", "PROBLEM", 71, 98], ["parainfluenza viruses (PIVs", "TREATMENT", 111, 138], ["human metapneumovirus", "PROBLEM", 150, 171], ["hMPV", "PROBLEM", 173, 177], ["syncytial virus", "OBSERVATION", 83, 98], ["metapneumovirus", "OBSERVATION", 156, 171]]], ["Longitudinal community-based surveillance studies conducted in the 1960s\u20131980s found that RSV and PIVs accounted for many ARIs [6, 20\u201324] yet few recent studies have assessed their population-wide burden and little is known about the incidence of hMPV in the general population.", [["PIVs", "DISEASE", 98, 102], ["hMPV", "DISEASE", 247, 251], ["RSV", "ORGANISM", 90, 93], ["hMPV", "ORGANISM", 247, 251], ["RSV", "SPECIES", 90, 93], ["hMPV", "SPECIES", 247, 251], ["surveillance studies", "TEST", 29, 49], ["RSV", "PROBLEM", 90, 93], ["PIVs", "TREATMENT", 98, 102], ["many ARIs", "PROBLEM", 117, 126], ["hMPV", "PROBLEM", 247, 251], ["RSV", "OBSERVATION", 90, 93], ["PIVs", "OBSERVATION", 98, 102], ["wide", "OBSERVATION_MODIFIER", 192, 196], ["burden", "OBSERVATION", 197, 203], ["hMPV", "OBSERVATION", 247, 251]]], ["Finally, while rhinoviruses (RVs) [25], coronaviruses (CoVs) [26], and other viruses [2] are known to cause medically attended ARI-related visits, studies on their population-wide burden are lacking.", [["ARI", "DISEASE", 127, 130], ["rhinoviruses", "ORGANISM", 15, 27], ["coronaviruses", "ORGANISM", 40, 53], ["CoVs", "GENE_OR_GENE_PRODUCT", 55, 59], ["rhinoviruses", "PROBLEM", 15, 27], ["coronaviruses (CoVs)", "PROBLEM", 40, 60]]], ["Such knowledge could guide future vaccine development.INTRODUCTIONWe conducted a prospective, population-wide surveillance study in two distinct geographical areas to assess the incidence of ARIs during the winter months.", [["ARIs", "DISEASE", 191, 195], ["future vaccine development", "TREATMENT", 27, 53], ["wide surveillance study", "TEST", 105, 128], ["ARIs", "PROBLEM", 191, 195]]], ["Our objectives were to (1) estimate, at the population level, the incidence of ARIs across the age spectrum; (2) identify the common viruses currently causing ARIs throughout the community and their relative frequency; (3) compare the types of viruses causing ARIs in child vs. adult populations; and (4) estimate the proportion of individuals in the community with ARIs who make a healthcare visit.Study design ::: MATERIAL AND METHODSOur prospective, population-wide surveillance study used a previously described rolling cross-sectional (RCS) study design [27] in two communities (Rochester, NY and Marshfield, WI) in the 2011 winter season to identify individuals with ARIs (defined as a current illness with feverishness or cough within the past 7 days) and document viruses associated with these ARIs.", [["ARIs", "DISEASE", 79, 83], ["ARIs", "DISEASE", 260, 264], ["ARIs", "DISEASE", 673, 677], ["illness", "DISEASE", 700, 707], ["feverishness", "DISEASE", 713, 725], ["cough", "DISEASE", 729, 734], ["ARIs", "DISEASE", 802, 806], ["ARIs", "CANCER", 260, 264], ["ARIs", "PROBLEM", 79, 83], ["the common viruses", "PROBLEM", 122, 140], ["ARIs", "PROBLEM", 159, 163], ["viruses", "PROBLEM", 244, 251], ["ARIs", "PROBLEM", 260, 264], ["wide surveillance study", "TEST", 464, 487], ["ARIs", "PROBLEM", 673, 677], ["feverishness", "PROBLEM", 713, 725], ["cough", "PROBLEM", 729, 734], ["viruses", "PROBLEM", 772, 779], ["these ARIs", "PROBLEM", 796, 806], ["common", "ANATOMY", 126, 132], ["viruses", "OBSERVATION", 133, 140], ["viruses", "OBSERVATION", 244, 251]]], ["The RCS design was first described and used by political scientists in the early 1980s for studies of voter preferences and election results; it consists of a series of cross-sectional samples in which each sample is representative of the source population [28].", [["cross-sectional samples", "TEST", 169, 192]]], ["A random sample of subjects was selected each week and then interviewed by telephone to identify those with ARIs and to obtain demographic and disease-specific information.", [["ARIs", "DISEASE", 108, 112], ["subjects", "ORGANISM", 19, 27]]], ["Consenting individuals provided nasal and throat swabs which were tested in a research laboratory by real-time polymerase chain reaction (rPCR) for a wide spectrum of viruses.Study setting and sampling frame ::: MATERIAL AND METHODSWe performed the study in two communities labelled \u2018Rochester\u2019 and \u2018Marshfield\u2019: (a) Monroe County, NY surrounding the city of Rochester (population ~744 000); and (b) the Marshfield, Wisconsin area (population ~49 000).", [["nasal", "ANATOMY", 32, 37], ["throat swabs", "ANATOMY", 42, 54], ["individuals", "ORGANISM", 11, 22], ["nasal", "ORGANISM_SUBDIVISION", 32, 37], ["nasal and throat swabs", "TEST", 32, 54], ["a wide spectrum of viruses", "PROBLEM", 148, 174], ["the study", "TEST", 245, 254], ["nasal", "ANATOMY", 32, 37], ["throat", "ANATOMY", 42, 48], ["viruses", "OBSERVATION", 167, 174]]], ["The Rochester sampling frame comprised 12 primary-care practices (six internal medicine, four paediatric, one family medicine, and one medicine-paediatrics practice) serving 90 245 patients whose age, race/ethnicity, and health insurance mirrored the demographics of Monroe County.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189]]], ["The Marshfield sampling frame consisted of 49 000 residents of the Marshfield Epidemiologic Study Area (MESA), a population-based cohort of residents living in 14 zip codes surrounding Marshfield; >90% of MESA resident receive their healthcare at Marshfield Clinic [30].Subject identification ::: MATERIAL AND METHODSThe study focused on individuals (not households).", [["individuals", "ORGANISM", 338, 349], ["METHODSThe study", "TEST", 310, 326]]], ["Participants were identified at random from the two source populations.", [["Participants", "SPECIES", 0, 12]]], ["In Rochester, we created a denominator of all eligible individuals by merging the practice-level patient databases across 12 practices.", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104]]], ["We used random digit-dialling to call the primary contact telephone number (mobile or land-line) and called 490\u2013825 people/week (based on previous power calculations), enrolling 118\u2013247 subjects/week.", [["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122]]], ["In both communities, a person was eligible if he/she was aged \u2a7e6 months as of 1 January, had at least one healthcare encounter in the previous 24 months, and was a resident of Monroe County (Rochester) or a member of MESA (Marshfield) for \u2a7e12 continuous months prior to 1 January or since birth for those aged <1 year.", [["person", "SPECIES", 23, 29]]], ["Rochester subjects received a letter from their primary-care physician explaining the study and that an interviewer would telephone them for consent to participate.Surveillance timelines ::: MATERIAL AND METHODSUsing protocols developed by the CDC-funded New Vaccine Surveillance Network [2] and Influenza Vaccine Effectiveness (VE) Network [31], the two sites initiated telephone calls when the University laboratories (Rochester) or the Marshfield Laboratories and Wisconsin State Laboratory of Hygiene identified \u2a7e2 positive influenza specimens within 1 week or one positive specimen/week for 2 consecutive weeks, and stopped calls when laboratories failed to meet this threshold.", [["specimens", "ANATOMY", 538, 547], ["specimen", "ANATOMY", 578, 586], ["the study", "TEST", 82, 91], ["METHODSUsing protocols", "TREATMENT", 204, 226], ["the CDC", "TEST", 240, 247], ["New Vaccine Surveillance Network", "TREATMENT", 255, 287], ["Influenza Vaccine Effectiveness", "TREATMENT", 296, 327], ["positive influenza specimens", "PROBLEM", 519, 547]]], ["The surveillance periods were 11 January 2011 to 1 April 2011 (Rochester) and 17 January 2011 to 8 April 2011 (Marshfield), identical to surveillance in a parallel study of influenza vaccine effectiveness [31].Telephone interview process ::: MATERIAL AND METHODSWe used trained telephone interviewers to perform structured interviews.", [["influenza", "DISEASE", 173, 182], ["a parallel study", "TEST", 153, 169], ["influenza vaccine effectiveness", "TREATMENT", 173, 204]]], ["On Monday\u2013Friday in both communities, study enrollers were given a list of new patients to call and attempted to contact individuals on their assigned day for verbal consent and an interview.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["Up to three calls (morning, afternoon, early evening) were made per day to telephone numbers listed on practice patient lists.", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119]]], ["Individuals from the source population could be eligible more than once in subsequent weeks (96% of those who agreed to participate were enrolled once).Content of telephone interviews ::: MATERIAL AND METHODSTelephone interviewers screened subjects for ARI symptoms in the identified person (subject or child) over the past 7 days, described the study, and obtained verbal consent for a survey that included a symptom assessment.", [["ARI symptoms", "DISEASE", 253, 265], ["person", "SPECIES", 284, 290], ["ARI symptoms", "PROBLEM", 253, 265], ["the study", "TEST", 342, 351], ["a survey", "TEST", 385, 393], ["a symptom assessment", "TEST", 408, 428]]], ["Subjects with ARI symptoms in the past 7 days were defined as ARI positive; the remainder were defined as ARI negative.Content of telephone interviews ::: MATERIAL AND METHODSIn Rochester, if the sampled person was a child aged \u2a7d17 years, the interviewer spoke with a parent or guardian.", [["ARI", "DISEASE", 14, 17], ["ARI", "DISEASE", 106, 109], ["Subjects", "ORGANISM", 0, 8], ["person", "ORGANISM", 204, 210], ["person", "SPECIES", 204, 210], ["child", "SPECIES", 217, 222], ["ARI symptoms", "PROBLEM", 14, 26], ["ARI positive", "PROBLEM", 62, 74], ["ARI", "TEST", 106, 109]]], ["The interviewer conducted a brief computer-assisted interview to determine if the subject had new onset of feverishness or cough within 7 days.Content of telephone interviews ::: MATERIAL AND METHODSTelephone procedures in Marshfield were the same except: parents were interviewed if subjects were aged \u2a7d12 years; subjects aged 13\u201318 years were interviewed but with parental consent.Content of telephone interviews ::: MATERIAL AND METHODSIf a potential subject with an ARI was identified, the telephone interviewer obtained the date of symptom onset and specific symptoms experienced (using a checklist of symptoms), and asked for verbal consent for an in-person visit to conduct an interview and collect nasal/throat specimens for viral testing; they were compensated $20 for a home visit or $30 for a clinic visit (or community site).", [["nasal", "ANATOMY", 706, 711], ["throat specimens", "ANATOMY", 712, 728], ["feverishness", "DISEASE", 107, 119], ["cough", "DISEASE", 123, 128], ["ARI", "DISEASE", 470, 473], ["nasal", "ORGANISM_SUBDIVISION", 706, 711], ["feverishness", "PROBLEM", 107, 119], ["cough", "PROBLEM", 123, 128], ["METHODSTelephone procedures", "TREATMENT", 192, 219], ["an ARI", "PROBLEM", 467, 473], ["symptom onset", "PROBLEM", 537, 550], ["specific symptoms", "PROBLEM", 555, 572], ["symptoms", "PROBLEM", 607, 615], ["nasal/throat specimens", "TEST", 706, 728], ["viral testing", "TEST", 733, 746], ["cough", "OBSERVATION", 123, 128], ["throat", "ANATOMY", 712, 718]]], ["Subjects with no ARI symptoms were compensated with a $5 gift card.In-person interviews and specimen collection ::: MATERIAL AND METHODSIn-person visits were conducted within 7 days of the onset of illness symptoms to (1) obtain written consent for specimens and access to subjects\u2019 medical records for ARI-related information, (2) complete a brief interview to gather additional health-related information (ARI symptoms \u2a7d7 days, and in Rochester \u2013 sites for medical care for the ARI), and (3) obtain nasal/throat swabs for testing for viruses.", [["specimen", "ANATOMY", 92, 100], ["specimens", "ANATOMY", 249, 258], ["nasal", "ANATOMY", 501, 506], ["ARI", "DISEASE", 17, 20], ["illness", "DISEASE", 198, 205], ["ARI", "DISEASE", 303, 306], ["ARI", "DISEASE", 480, 483], ["Subjects", "ORGANISM", 0, 8], ["nasal", "ORGANISM_SUBDIVISION", 501, 506], ["throat", "ORGANISM", 507, 513], ["person", "SPECIES", 70, 76], ["person", "SPECIES", 139, 145], ["ARI symptoms", "PROBLEM", 17, 29], ["illness symptoms", "PROBLEM", 198, 214], ["ARI", "PROBLEM", 303, 306], ["ARI symptoms", "PROBLEM", 408, 420], ["medical care", "TREATMENT", 459, 471], ["the ARI", "PROBLEM", 476, 483], ["nasal/throat swabs", "TEST", 501, 519], ["testing", "TEST", 524, 531], ["viruses", "PROBLEM", 536, 543], ["nasal", "ANATOMY", 501, 506], ["throat", "ANATOMY", 507, 513]]], ["Enrollers collected one nasal and one throat swab for testing.Medical chart (electronic medical record) reviews ::: MATERIAL AND METHODSTrained abstractors reviewed medical records of ARI-positive cases for: (1) ARI-related healthcare visits (primary care, speciailty, ED, urgent care, or hospitalization) occurring within 7 days before or after the interview; (2) procedures obtained during visits (chest radiograph, bloodwork, nasopharyngeal or respiratory cultures, rapid antigen testing); and (3) primary diagnosis for outpatient and ED visits and all diagnoses for hospitalizations.Laboratory procedures ::: MATERIAL AND METHODSNasal/throat specimens were combined in transport media, processed and stored at \u221280 \u00b0C. Laboratory testing was performed at the University of Rochester.", [["nasal", "ANATOMY", 24, 29], ["throat swab", "ANATOMY", 38, 49], ["chest", "ANATOMY", 400, 405], ["nasopharyngeal", "ANATOMY", 429, 443], ["respiratory", "ANATOMY", 447, 458], ["throat specimens", "ANATOMY", 639, 655], ["ARI", "DISEASE", 184, 187], ["ARI", "DISEASE", 212, 215], ["nasal", "ORGANISM_SUBDIVISION", 24, 29], ["throat swab", "ORGANISM_SUBDIVISION", 38, 49], ["throat specimens", "CANCER", 639, 655], ["one throat swab", "TEST", 34, 49], ["testing", "TEST", 54, 61], ["ARI", "PROBLEM", 184, 187], ["ARI", "PROBLEM", 212, 215], ["chest radiograph", "TEST", 400, 416], ["bloodwork", "TEST", 418, 427], ["nasopharyngeal or respiratory cultures", "TEST", 429, 467], ["rapid antigen testing", "TEST", 469, 490], ["METHODSNasal/throat specimens", "TREATMENT", 626, 655], ["Laboratory testing", "TEST", 722, 740], ["chest", "ANATOMY", 400, 405], ["nasopharyngeal", "ANATOMY", 429, 443], ["respiratory", "ANATOMY", 447, 458], ["throat", "ANATOMY", 639, 645]]], ["Total nucleic acid was extracted according to the manufacturer's protocol using the QIAamp Viral RNA Mini kit on a QIAcube robotic instrument (Qiagen, USA).", [["nucleic acid", "CHEMICAL", 6, 18], ["Total nucleic acid", "TREATMENT", 0, 18], ["the QIAamp", "TREATMENT", 80, 90], ["a QIAcube robotic instrument", "TREATMENT", 113, 141]]], ["Specimens were tested by TaqMan Array Card (TAC) methodology (Life Technologies, USA), which allows simultaneous, singleplex, rPCR to be performed in a 384-well microfluidic card format [32].", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["We tested specimens for influenza virues A and B, RSV, PIV1\u20134, RV, adenovirus, hMVP, and CoVs 229E, NL63, OC43 and HKU1 by TAC assay.", [["specimens", "ANATOMY", 10, 19], ["TAC", "CHEMICAL", 123, 126], ["B", "GENE_OR_GENE_PRODUCT", 47, 48], ["RSV", "ORGANISM", 50, 53], ["PIV1\u20134", "GENE_OR_GENE_PRODUCT", 55, 61], ["RV", "GENE_OR_GENE_PRODUCT", 63, 65], ["adenovirus", "ORGANISM", 67, 77], ["hMVP", "GENE_OR_GENE_PRODUCT", 79, 83], ["CoVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["NL63", "GENE_OR_GENE_PRODUCT", 100, 104], ["OC43", "GENE_OR_GENE_PRODUCT", 106, 110], ["HKU1", "GENE_OR_GENE_PRODUCT", 115, 119], ["OC43", "PROTEIN", 106, 110], ["HKU1", "PROTEIN", 115, 119], ["RSV", "SPECIES", 50, 53], ["PIV1\u20134", "SPECIES", 55, 61], ["RV", "SPECIES", 63, 65], ["adenovirus", "SPECIES", 67, 77], ["specimens", "TEST", 10, 19], ["influenza", "PROBLEM", 24, 33], ["RSV", "TEST", 50, 53], ["PIV1\u20134", "TEST", 55, 61], ["RV", "TEST", 63, 65], ["adenovirus", "PROBLEM", 67, 77], ["hMVP", "TEST", 79, 83], ["CoVs", "TEST", 89, 93], ["NL63", "TEST", 100, 104], ["OC43", "TEST", 106, 110], ["HKU1", "TEST", 115, 119], ["RV", "ANATOMY", 63, 65]]], ["All primer and probe oligonucleotide sequences used for PCR assays were prepared and optimized by CDC.", [["All primer", "TREATMENT", 0, 10], ["probe oligonucleotide sequences", "TEST", 15, 46], ["PCR assays", "TEST", 56, 66]]], ["TAC assays demonstrated high sensitivity (75\u201395%) for influenza, RSV, PIV2\u20134, RV, and hMPV, and moderate sensitivity (54\u201356%) for PIV1 and adenovirus compared with individual-virus PCRs [33].", [["TAC", "CHEMICAL", 0, 3], ["influenza", "DISEASE", 54, 63], ["TAC", "CHEMICAL", 0, 3], ["RSV", "ORGANISM", 65, 68], ["PIV2\u20134", "GENE_OR_GENE_PRODUCT", 70, 76], ["hMPV", "ORGANISM", 86, 90], ["PIV1", "GENE_OR_GENE_PRODUCT", 130, 134], ["adenovirus", "ORGANISM", 139, 149], ["RSV", "SPECIES", 65, 68], ["PIV2\u20134", "SPECIES", 70, 76], ["RV", "SPECIES", 78, 80], ["hMPV", "SPECIES", 86, 90], ["PIV1", "SPECIES", 130, 134], ["adenovirus", "SPECIES", 139, 149], ["TAC assays", "TEST", 0, 10], ["high sensitivity", "PROBLEM", 24, 40], ["influenza", "PROBLEM", 54, 63], ["RSV", "TEST", 65, 68], ["PIV2\u20134", "TEST", 70, 76], ["RV", "TEST", 78, 80], ["hMPV", "PROBLEM", 86, 90], ["moderate sensitivity", "PROBLEM", 96, 116], ["PIV1", "PROBLEM", 130, 134], ["adenovirus", "PROBLEM", 139, 149], ["high", "OBSERVATION_MODIFIER", 24, 28], ["RV", "ANATOMY", 78, 80], ["moderate", "OBSERVATION_MODIFIER", 96, 104]]], ["The four CoV rPCR assays were highly sensitive and specific for the detection of CoV 229E, NL63, OC43 and HKU1, with positive predictive values in the TAC assay of 94%, 97%, 96% and 88%, respectively [34].Statistical analyses ::: MATERIAL AND METHODSWe assessed the frequency of each virus and also multiple viruses and tabulated results for all subjects, by age [child (6 months\u201318\u00b79 years) vs. adult], setting (Rochester vs. Marshfield), and whether subjects had sought medical care for ARIs.", [["ARIs", "DISEASE", 489, 493], ["CoV", "ORGANISM", 9, 12], ["CoV", "ORGANISM", 81, 84], ["229E", "GENE_OR_GENE_PRODUCT", 85, 89], ["NL63", "GENE_OR_GENE_PRODUCT", 91, 95], ["OC43", "GENE_OR_GENE_PRODUCT", 97, 101], ["HKU1", "GENE_OR_GENE_PRODUCT", 106, 110], ["CoV 229E", "SPECIES", 81, 89], ["The four CoV rPCR assays", "TEST", 0, 24], ["the detection", "TEST", 64, 77], ["CoV", "TEST", 81, 84], ["NL63", "TEST", 91, 95], ["OC43", "TEST", 97, 101], ["HKU1", "TEST", 106, 110], ["the TAC assay", "TEST", 147, 160], ["each virus", "PROBLEM", 279, 289], ["multiple viruses", "PROBLEM", 299, 315], ["ARIs", "PROBLEM", 489, 493], ["multiple", "OBSERVATION_MODIFIER", 299, 307], ["viruses", "OBSERVATION", 308, 315]]], ["We used tabular analyses to summarize diagnoses/procedures for subjects with ARI-related medical visits.", [["ARI", "DISEASE", 77, 80], ["ARI", "PROBLEM", 77, 80]]], ["We used Pearson's \u03c72 tests to compare individual viruses between adult and child ARI positive subjects.", [["ARI", "DISEASE", 81, 84], ["Pearson's \u03c72 tests", "TEST", 8, 26]]], ["In instances where expected values were 1\u20135 we corrected the \u03c72 test statistic with the N \u2013 1 correction, and used Fisher's exact test when expected cell sizes were <1 [35].", [["cell", "ANATOMY", 149, 153], ["cell", "CELL", 149, 153], ["Fisher's exact test", "TEST", 115, 134], ["expected cell sizes", "TEST", 140, 159]]], ["We estimated population-wide ARI and individual virus cumulative incidence during the 3-month study period by summing the percent of the population that had a new ARI (symptoms for \u2a7d7 days) each week (i.e. weekly incidence).", [["ARI", "DISEASE", 29, 32], ["ARI", "DISEASE", 163, 166], ["wide ARI", "PROBLEM", 24, 32], ["a new ARI (symptoms", "PROBLEM", 157, 176], ["population", "OBSERVATION_MODIFIER", 13, 23], ["wide ARI", "OBSERVATION_MODIFIER", 24, 32], ["virus", "OBSERVATION_MODIFIER", 48, 53]]], ["For instance, if we had run a 3-week RCS, and weekly incidences were 2%, 3% and 4%, we would calculate the cumulative incidence as 9%.Statistical analyses ::: MATERIAL AND METHODSWe used a stratified biased corrected and accelerated bootstrap procedure to calculate 95% confidence intervals (CIs) for population-wide proportions, with 1000 replications [36].Incidence of ARIs during the influenza season (Fig. 1fig01fig) ::: RESULTSIn Rochester, 17 485 telephone calls were made, 4130 calls were completed (i.e. direct contact with a household member), 2683 (65%) agreed to participate in symptom assessment and were enrolled, of whom 2263 (84%) consented for medical chart review for influenza vaccination dates.", [["ARIs", "DISEASE", 371, 375], ["influenza", "DISEASE", 387, 396], ["influenza", "DISEASE", 685, 694], ["accelerated bootstrap procedure", "TREATMENT", 221, 252], ["CIs", "TEST", 292, 295], ["ARIs", "PROBLEM", 371, 375], ["symptom assessment", "TEST", 589, 607], ["influenza vaccination", "TREATMENT", 685, 706]]], ["Altogether, 98 nasal/throat specimens were collected (64% of ARI subjects); one specimen was invalid with no ribonucleoprotein (RNP) human cellular control detected.", [["nasal", "ANATOMY", 15, 20], ["throat specimens", "ANATOMY", 21, 37], ["specimen", "ANATOMY", 80, 88], ["cellular", "ANATOMY", 139, 147], ["throat specimens", "CANCER", 21, 37], ["RNP", "CELLULAR_COMPONENT", 128, 131], ["human", "ORGANISM", 133, 138], ["cellular", "CELL", 139, 147], ["RNP", "PROTEIN", 128, 131], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["nasal/throat specimens", "TEST", 15, 37], ["ARI subjects", "TEST", 61, 73], ["one specimen", "TEST", 76, 88], ["ribonucleoprotein (RNP", "TREATMENT", 109, 131], ["human cellular control", "TREATMENT", 133, 155], ["throat", "ANATOMY", 21, 27], ["cellular control", "OBSERVATION", 139, 155]]], ["Of individuals contacted by telephone, 153 had an ARI with feverishness or cough for a weekly (i.e. ARI within the previous 6 days) mean ARI incidence of 5\u00b77%.", [["ARI", "DISEASE", 50, 53], ["feverishness", "DISEASE", 59, 71], ["cough", "DISEASE", 75, 80], ["ARI", "DISEASE", 137, 140], ["an ARI", "PROBLEM", 47, 53], ["feverishness", "PROBLEM", 59, 71], ["cough", "PROBLEM", 75, 80], ["ARI", "PROBLEM", 100, 103], ["mean ARI incidence", "PROBLEM", 132, 150], ["cough", "OBSERVATION", 75, 80]]], ["The cumulative incidence for ARI during the 3-month study period was 52% (95% CI 42\u201363) as shown in Figure 2.", [["ARI", "DISEASE", 29, 32], ["ARI", "PROBLEM", 29, 32], ["CI", "TEST", 78, 80]]], ["It was 21% when restricted to subjects for whom a viral respiratory pathogen was detected (95% CI 15\u201328).", [["viral respiratory pathogen", "DISEASE", 50, 76], ["a viral respiratory pathogen", "PROBLEM", 48, 76]]]], "PMC7255895": [["IntroductionThe current rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19), calls for a rapid response from the research community.", [["acute respiratory syndrome coronavirus", "DISEASE", 47, 85], ["coronavirus disease", "DISEASE", 109, 128], ["SARS-CoV-2", "ORGANISM", 89, 99], ["coronavirus", "ORGANISM", 109, 120], ["severe acute respiratory syndrome coronavirus", "SPECIES", 40, 85], ["SARS-CoV-2", "SPECIES", 89, 99], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 40, 85], ["SARS-CoV", "TEST", 89, 97], ["coronavirus disease", "PROBLEM", 109, 128], ["COVID", "TEST", 135, 140], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory syndrome", "OBSERVATION", 53, 73], ["coronavirus disease", "OBSERVATION", 109, 128]]], ["Lithium is known to exhibit antiviral activity, but the knowledge of its potential as a possible therapy for coronoviral infections has not been summarized yet.", [["Lithium", "CHEMICAL", 0, 7], ["coronoviral infections", "DISEASE", 109, 131], ["Lithium", "CHEMICAL", 0, 7], ["Lithium", "SIMPLE_CHEMICAL", 0, 7], ["Lithium", "TREATMENT", 0, 7], ["antiviral activity", "PROBLEM", 28, 46], ["therapy", "TREATMENT", 97, 104], ["coronoviral infections", "PROBLEM", 109, 131], ["antiviral activity", "OBSERVATION", 28, 46]]], ["The aim of this brief report is to draw attention to lithium as potential COVID-19 treatment and prophylaxis.MethodsOn February 1st 2020 the following PubMed search was conducted with no language or time restrictions: (lithium and (coronavirus or *coronavirus or sarbecovirus or SARS or \u201csevere acute respiratory syndrome\u201d or MERS or \u201cMiddle East respiratory syndrome\u201d or nobecovirus or merbecovirus or hibecovirus or embecovirus or andecovirus or buldecovirus or herdecovirus or moordecovirus or cegacovirus or igacovirus or \u201cmicrohyla lentovirus\u201d or milecovirus or alphaletovirus or tegacovirus or setracovirus or rhinacovirus or pedacovirus or \u201cporcine epidemic diarrhea\u201d or nyctacovirus or \u201cnectalus velutinus\u201d or myotacovirus or \u201cmyotis ricketti\u201d or minunacovirus or minacovirus or luchacovirus or duvinacovirus or decacovirus or \u201cRhinolophus ferrumequinum\u201d or \u201ctransmissible gastroenteritis virus\u201d or \u201cfeline infectious peritonitis virus\u201d or \u201ccanine coronavirus\u201d or \u201cmurine hepatitis virus\u201d)).", [["lithium", "CHEMICAL", 53, 60], ["COVID-19", "CHEMICAL", 74, 82], ["lithium", "CHEMICAL", 219, 226], ["SARS", "DISEASE", 279, 283], ["acute respiratory syndrome", "DISEASE", 295, 321], ["Middle East respiratory syndrome", "DISEASE", 335, 367], ["diarrhea", "DISEASE", 665, 673], ["gastroenteritis", "DISEASE", 881, 896], ["peritonitis", "DISEASE", 926, 937], ["coronavirus", "DISEASE", 956, 967], ["hepatitis", "DISEASE", 980, 989], ["lithium", "CHEMICAL", 53, 60], ["COVID-19", "CHEMICAL", 74, 82], ["lithium", "CHEMICAL", 219, 226], ["lithium", "SIMPLE_CHEMICAL", 53, 60], ["*coronavirus", "ORGANISM", 247, 259], ["murine hepatitis virus", "ORGANISM", 973, 995], ["porcine", "SPECIES", 648, 655], ["nectalus velutinus", "SPECIES", 695, 713], ["myotis ricketti", "SPECIES", 735, 750], ["Rhinolophus ferrumequinum", "SPECIES", 836, 861], ["feline", "SPECIES", 908, 914], ["canine", "SPECIES", 949, 955], ["coronavirus", "SPECIES", 956, 967], ["murine", "SPECIES", 973, 979], ["Rhinolophus ferrumequinum", "SPECIES", 836, 861], ["canine", "SPECIES", 949, 955], ["lithium", "TREATMENT", 53, 60], ["potential COVID-19 treatment", "TREATMENT", 64, 92], ["prophylaxis", "TREATMENT", 97, 108], ["lithium and (coronavirus", "PROBLEM", 219, 243], ["coronavirus", "PROBLEM", 248, 259], ["sarbecovirus", "PROBLEM", 263, 275], ["SARS", "PROBLEM", 279, 283], ["\u201csevere acute respiratory syndrome", "PROBLEM", 287, 321], ["MERS", "PROBLEM", 326, 330], ["Middle East respiratory syndrome", "PROBLEM", 335, 367], ["nobecovirus", "PROBLEM", 372, 383], ["merbecovirus", "PROBLEM", 387, 399], ["hibecovirus", "PROBLEM", 403, 414], ["embecovirus", "PROBLEM", 418, 429], ["andecovirus", "PROBLEM", 433, 444], ["buldecovirus", "PROBLEM", 448, 460], ["herdecovirus", "PROBLEM", 464, 476], ["moordecovirus", "PROBLEM", 480, 493], ["cegacovirus", "PROBLEM", 497, 508], ["igacovirus", "PROBLEM", 512, 522], ["\u201cmicrohyla lentovirus\u201d", "PROBLEM", 526, 548], ["milecovirus", "PROBLEM", 552, 563], ["alphaletovirus", "PROBLEM", 567, 581], ["tegacovirus", "PROBLEM", 585, 596], ["setracovirus", "PROBLEM", 600, 612], ["rhinacovirus", "PROBLEM", 616, 628], ["pedacovirus", "PROBLEM", 632, 643], ["porcine epidemic diarrhea", "PROBLEM", 648, 673], ["nyctacovirus", "PROBLEM", 678, 690], ["nectalus velutinus\u201d", "PROBLEM", 695, 714], ["myotacovirus", "PROBLEM", 718, 730], ["myotis ricketti\u201d", "PROBLEM", 735, 751], ["minunacovirus", "PROBLEM", 755, 768], ["minacovirus", "PROBLEM", 772, 783], ["luchacovirus", "PROBLEM", 787, 799], ["duvinacovirus", "PROBLEM", 803, 816], ["decacovirus", "PROBLEM", 820, 831], ["Rhinolophus ferrumequinum\u201d", "PROBLEM", 836, 862], ["\u201ctransmissible gastroenteritis virus\u201d", "PROBLEM", 866, 903], ["\u201cfeline infectious peritonitis virus", "PROBLEM", 907, 943], ["canine coronavirus", "PROBLEM", 949, 967], ["murine hepatitis virus", "PROBLEM", 973, 995], ["severe", "OBSERVATION_MODIFIER", 288, 294], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["respiratory syndrome", "OBSERVATION", 301, 321], ["Middle", "ANATOMY_MODIFIER", 335, 341]]], ["The search yielded 45 articles, of which all the abstracts were charted and reviewed by two researchers.ResultsSix studies reporting on the influence of lithium on coronaviral infections were identified (Figure 1).ResultsIn Vero cells, lithium chloride (investigated at 1\u201315 mM) was shown to be dose-dependently effective in suppressing infection with the porcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family1.", [["coronaviral", "ANATOMY", 164, 175], ["Vero cells", "ANATOMY", 224, 234], ["lithium", "CHEMICAL", 153, 160], ["coronaviral infections", "DISEASE", 164, 186], ["lithium chloride", "CHEMICAL", 236, 252], ["infection", "DISEASE", 337, 346], ["porcine epidemic diarrhea", "DISEASE", 356, 381], ["lithium", "CHEMICAL", 153, 160], ["lithium chloride", "CHEMICAL", 236, 252], ["lithium", "SIMPLE_CHEMICAL", 153, 160], ["Vero cells", "CELL", 224, 234], ["lithium chloride", "SIMPLE_CHEMICAL", 236, 252], ["porcine epidemic diarrhea virus", "ORGANISM", 356, 387], ["PEDV", "ORGANISM", 389, 393], ["Vero cells", "CELL_LINE", 224, 234], ["porcine epidemic diarrhea virus", "SPECIES", 356, 387], ["porcine epidemic diarrhea virus", "SPECIES", 356, 387], ["PEDV", "SPECIES", 389, 393], ["ResultsSix studies", "TEST", 104, 122], ["lithium", "TREATMENT", 153, 160], ["coronaviral infections", "PROBLEM", 164, 186], ["lithium chloride", "TREATMENT", 236, 252], ["suppressing infection", "PROBLEM", 325, 346], ["the porcine epidemic diarrhea virus", "PROBLEM", 352, 387], ["infections", "OBSERVATION", 176, 186], ["infection", "OBSERVATION", 337, 346]]], ["Not only PEDV entry and replication were inhibited in the presence of LiCl, but apoptosis as well.", [["LiCl", "CHEMICAL", 70, 74], ["LiCl", "CHEMICAL", 70, 74], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["LiCl", "SIMPLE_CHEMICAL", 70, 74], ["apoptosis", "PROBLEM", 80, 89], ["LiCl", "OBSERVATION", 70, 74], ["apoptosis", "OBSERVATION", 80, 89]]], ["Yet, LiCl at 1 mM (safe in patients) was not effective.", [["LiCl", "CHEMICAL", 5, 9], ["LiCl", "CHEMICAL", 5, 9], ["LiCl", "SIMPLE_CHEMICAL", 5, 9], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["At 5 mM LiCl reduced viral RNA levels by 30% (p < 0.001).", [["LiCl", "CHEMICAL", 8, 12], ["LiCl", "CHEMICAL", 8, 12], ["LiCl", "SIMPLE_CHEMICAL", 8, 12], ["viral RNA", "RNA", 21, 30], ["viral RNA levels", "TEST", 21, 37], ["viral RNA", "OBSERVATION", 21, 30]]], ["In MARC-145 cells, LiCl reduced the production of RNA and proteins specific to the porcine reproductive and respiratory syndrome virus.", [["MARC-145 cells", "ANATOMY", 3, 17], ["LiCl", "CHEMICAL", 19, 23], ["porcine reproductive and respiratory syndrome", "DISEASE", 83, 128], ["LiCl", "CHEMICAL", 19, 23], ["MARC-145 cells", "CELL", 3, 17], ["LiCl", "SIMPLE_CHEMICAL", 19, 23], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 83, 134], ["MARC-145 cells", "CELL_LINE", 3, 17], ["LiCl", "TREATMENT", 19, 23], ["RNA and proteins", "PROBLEM", 50, 66], ["the porcine reproductive", "PROBLEM", 79, 103], ["respiratory syndrome virus", "PROBLEM", 108, 134], ["145 cells", "OBSERVATION_MODIFIER", 8, 17], ["respiratory syndrome", "OBSERVATION", 108, 128]]], ["The relative viral mRNA level decreased by more than 30% (p < 0.001) at the concentration of 10 mM and by 50% at 20 mM (p < 0.001).", [["viral mRNA", "RNA", 13, 23], ["The relative viral mRNA level", "TEST", 0, 29], ["viral mRNA", "OBSERVATION", 13, 23]]], ["The authors, however, cautioned that the effect might have been dependent on LiCl presence during the early stages of viral replication (first 9 hours) and the increase of tumor necrosis factor-\u03b1, which was greater following LiCl alone than induced by the virus2.In vitro studies of another porcine coronavirus causing transmissible gastroenteritis indicated that LiCl (5\u201325 mM) acts on both early and late stages of infection and inhibits apoptosis3.", [["LiCl", "CHEMICAL", 77, 81], ["tumor", "DISEASE", 172, 177], ["necrosis", "DISEASE", 178, 186], ["LiCl", "CHEMICAL", 225, 229], ["porcine coronavirus", "DISEASE", 291, 310], ["gastroenteritis", "DISEASE", 333, 348], ["LiCl", "CHEMICAL", 364, 368], ["infection", "DISEASE", 417, 426], ["LiCl", "CHEMICAL", 77, 81], ["LiCl", "CHEMICAL", 225, 229], ["LiCl", "CHEMICAL", 364, 368], ["LiCl", "SIMPLE_CHEMICAL", 77, 81], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 172, 195], ["LiCl", "SIMPLE_CHEMICAL", 225, 229], ["virus2", "GENE_OR_GENE_PRODUCT", 256, 262], ["porcine coronavirus", "ORGANISM", 291, 310], ["LiCl", "SIMPLE_CHEMICAL", 364, 368], ["tumor necrosis factor-\u03b1", "PROTEIN", 172, 195], ["virus2", "PROTEIN", 256, 262], ["porcine coronavirus", "SPECIES", 291, 310], ["porcine coronavirus", "SPECIES", 291, 310], ["viral replication", "PROBLEM", 118, 135], ["tumor necrosis factor", "PROBLEM", 172, 193], ["vitro studies", "TEST", 266, 279], ["another porcine coronavirus", "PROBLEM", 283, 310], ["transmissible gastroenteritis", "PROBLEM", 319, 348], ["LiCl", "TEST", 364, 368], ["infection", "PROBLEM", 417, 426], ["apoptosis3", "PROBLEM", 440, 450], ["viral replication", "OBSERVATION", 118, 135], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["tumor", "OBSERVATION_MODIFIER", 172, 177], ["necrosis", "OBSERVATION", 178, 186], ["gastroenteritis", "OBSERVATION", 333, 348], ["late stages", "OBSERVATION_MODIFIER", 402, 413], ["infection", "OBSERVATION", 417, 426]]], ["Both virus titer reduction and cell survival at 70\u201390% were achieved with LiCl at 25 mM (10\u201350% at 5 mM).", [["cell", "ANATOMY", 31, 35], ["LiCl", "CHEMICAL", 74, 78], ["LiCl", "CHEMICAL", 74, 78], ["cell", "CELL", 31, 35], ["LiCl", "SIMPLE_CHEMICAL", 74, 78], ["Both virus titer reduction", "TREATMENT", 0, 26], ["cell survival", "TEST", 31, 44], ["LiCl", "TEST", 74, 78], ["virus", "OBSERVATION_MODIFIER", 5, 10], ["titer", "OBSERVATION_MODIFIER", 11, 16], ["reduction", "OBSERVATION_MODIFIER", 17, 26]]], ["The same research group from Harbin in China reported earlier that LiCl (investigated at 5\u201350 mM) reduced the cytopathic effect of the avian infectious bronchitis virus (also a coronavirus) in primary chicken embryo kidney cells4.", [["embryo kidney cells4", "ANATOMY", 209, 229], ["LiCl", "CHEMICAL", 67, 71], ["infectious bronchitis virus", "DISEASE", 141, 168], ["LiCl", "CHEMICAL", 67, 71], ["LiCl", "SIMPLE_CHEMICAL", 67, 71], ["avian infectious bronchitis virus", "ORGANISM", 135, 168], ["coronavirus", "ORGANISM", 177, 188], ["chicken", "ORGANISM", 201, 208], ["embryo kidney cells4", "CELL", 209, 229], ["primary chicken embryo kidney cells4", "CELL_TYPE", 193, 229], ["avian infectious bronchitis virus", "SPECIES", 135, 168], ["chicken", "SPECIES", 201, 208], ["infectious bronchitis virus", "SPECIES", 141, 168], ["chicken", "SPECIES", 201, 208], ["the cytopathic effect", "PROBLEM", 106, 127], ["the avian infectious bronchitis virus", "PROBLEM", 131, 168], ["a coronavirus)", "PROBLEM", 175, 189], ["primary chicken embryo kidney cells4", "PROBLEM", 193, 229], ["cytopathic", "OBSERVATION_MODIFIER", 110, 120], ["infectious", "OBSERVATION_MODIFIER", 141, 151], ["bronchitis", "OBSERVATION", 152, 162], ["chicken embryo", "OBSERVATION", 201, 215], ["kidney", "ANATOMY", 216, 222]]], ["The results suggest that the dose of 5 mM was beneficial (20% inhibition) when applied one hour after infection, but not 8 hours post infection.", [["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 134, 143], ["infection", "PROBLEM", 102, 111], ["infection", "PROBLEM", 134, 143], ["infection", "OBSERVATION", 102, 111], ["infection", "OBSERVATION", 134, 143]]], ["In Vero cells, African green monkey kidney-derived epithelial cells, and immortalized chicken embryo fibroblasts LiCl suppressed the avian coronavirus infectious bronchitis.", [["Vero cells", "ANATOMY", 3, 13], ["kidney-derived epithelial cells", "ANATOMY", 36, 67], ["embryo fibroblasts", "ANATOMY", 94, 112], ["LiCl", "CHEMICAL", 113, 117], ["coronavirus infectious bronchitis", "DISEASE", 139, 172], ["LiCl", "CHEMICAL", 113, 117], ["Vero cells", "CELL", 3, 13], ["African green monkey kidney-derived epithelial cells", "CELL", 15, 67], ["chicken", "ORGANISM", 86, 93], ["embryo fibroblasts", "CELL", 94, 112], ["LiCl", "SIMPLE_CHEMICAL", 113, 117], ["avian coronavirus", "ORGANISM", 133, 150], ["Vero cells", "CELL_LINE", 3, 13], ["African green monkey kidney-derived epithelial cells", "CELL_TYPE", 15, 67], ["immortalized chicken embryo fibroblasts", "CELL_LINE", 73, 112], ["green monkey", "SPECIES", 23, 35], ["chicken", "SPECIES", 86, 93], ["avian coronavirus", "SPECIES", 133, 150], ["African green monkey", "SPECIES", 15, 35], ["chicken", "SPECIES", 86, 93], ["epithelial cells", "PROBLEM", 51, 67], ["immortalized chicken embryo fibroblasts LiCl", "TREATMENT", 73, 117], ["the avian coronavirus infectious bronchitis", "PROBLEM", 129, 172], ["Vero cells", "OBSERVATION", 3, 13], ["kidney", "ANATOMY", 36, 42], ["epithelial cells", "OBSERVATION", 51, 67], ["immortalized chicken embryo fibroblasts LiCl suppressed", "OBSERVATION", 73, 128], ["coronavirus", "OBSERVATION_MODIFIER", 139, 150], ["infectious", "OBSERVATION_MODIFIER", 151, 161], ["bronchitis", "OBSERVATION", 162, 172]]], ["Relative virus titers in both cell lines were reduced by at least 45% at 5 mM and 70\u201390% at 10 mM.", [["cell lines", "ANATOMY", 30, 40], ["cell lines", "CELL", 30, 40], ["cell lines", "CELL_LINE", 30, 40], ["Relative virus titers", "TEST", 0, 21], ["virus", "OBSERVATION_MODIFIER", 9, 14], ["titers", "OBSERVATION_MODIFIER", 15, 21], ["both", "ANATOMY_MODIFIER", 25, 29], ["cell lines", "OBSERVATION", 30, 40], ["reduced", "OBSERVATION_MODIFIER", 46, 53]]], ["Viral mRNA concentration decreased 20 times in both cell types cultured with 5 mM LiCl.", [["cell", "ANATOMY", 52, 56], ["LiCl", "CHEMICAL", 82, 86], ["LiCl", "CHEMICAL", 82, 86], ["Viral", "ORGANISM", 0, 5], ["cell", "CELL", 52, 56], ["LiCl", "SIMPLE_CHEMICAL", 82, 86], ["Viral mRNA", "RNA", 0, 10], ["Viral mRNA concentration", "TEST", 0, 24], ["5 mM LiCl", "TREATMENT", 77, 86], ["concentration", "OBSERVATION_MODIFIER", 11, 24], ["decreased", "OBSERVATION_MODIFIER", 25, 34], ["20 times", "OBSERVATION_MODIFIER", 35, 43]]], ["Overall, the antiviral activity of lithium was ascribed to a cellular effect5.", [["cellular", "ANATOMY", 61, 69], ["lithium", "CHEMICAL", 35, 42], ["lithium", "CHEMICAL", 35, 42], ["lithium", "SIMPLE_CHEMICAL", 35, 42], ["cellular", "CELL", 61, 69], ["lithium", "TREATMENT", 35, 42], ["antiviral activity", "OBSERVATION", 13, 31], ["cellular effect5", "OBSERVATION", 61, 77]]], ["One study was identified outside the main search reports on the activity of high LiCl concentrations (10\u201360 mM) against porcine deltacoronavirus: at 10 mM 50% relative mRNA reduction was found with no accompanying effect on the viral titer6.Putative molecular mechanisms ::: DiscussionThe major putative molecular mechanisms of antiviral activity and reduced apoptosis is the inhibition of glycogen synthase kinase 3-beta (GSK-3\u03b2)7,8.", [["LiCl", "CHEMICAL", 81, 85], ["deltacoronavirus", "CHEMICAL", 128, 144], ["glycogen", "CHEMICAL", 390, 398], ["LiCl", "CHEMICAL", 81, 85], ["LiCl", "SIMPLE_CHEMICAL", 81, 85], ["porcine", "ORGANISM", 120, 127], ["glycogen synthase kinase 3-beta", "GENE_OR_GENE_PRODUCT", 390, 421], ["GSK-3\u03b2)7,8", "GENE_OR_GENE_PRODUCT", 423, 433], ["glycogen synthase kinase 3-beta (GSK-3\u03b2)7,8", "PROTEIN", 390, 433], ["porcine", "SPECIES", 120, 127], ["One study", "TEST", 0, 9], ["high LiCl concentrations", "TREATMENT", 76, 100], ["porcine deltacoronavirus", "TREATMENT", 120, 144], ["relative mRNA reduction", "TREATMENT", 159, 182], ["the viral titer6", "PROBLEM", 224, 240], ["antiviral activity", "PROBLEM", 328, 346], ["reduced apoptosis", "PROBLEM", 351, 368], ["glycogen synthase kinase", "TEST", 390, 414], ["beta (GSK", "TEST", 417, 426], ["main", "OBSERVATION_MODIFIER", 37, 41], ["viral titer6", "OBSERVATION", 228, 240], ["molecular mechanisms", "OBSERVATION", 304, 324], ["antiviral activity", "OBSERVATION", 328, 346]]], ["However, lithium also inhibits GSK-3\u03b1, inositol monophosphatases, and may indirectly act via the electrolyte balance.Putative molecular mechanisms ::: DiscussionPEDV requires the PI3K/Akt/GSK-3\u03b1/\u03b2 pathway, which can be targeted at GSK-3\u03b2 by lithium9.", [["lithium", "CHEMICAL", 9, 16], ["inositol", "CHEMICAL", 39, 47], ["lithium", "CHEMICAL", 9, 16], ["inositol", "CHEMICAL", 39, 47], ["lithium9", "CHEMICAL", 241, 249], ["lithium", "SIMPLE_CHEMICAL", 9, 16], ["GSK-3\u03b1", "GENE_OR_GENE_PRODUCT", 31, 37], ["inositol monophosphatases", "SIMPLE_CHEMICAL", 39, 64], ["electrolyte", "SIMPLE_CHEMICAL", 97, 108], ["PI3K", "GENE_OR_GENE_PRODUCT", 179, 183], ["Akt", "GENE_OR_GENE_PRODUCT", 184, 187], ["GSK-3\u03b1", "GENE_OR_GENE_PRODUCT", 188, 194], ["\u03b2", "GENE_OR_GENE_PRODUCT", 195, 196], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 231, 237], ["lithium9", "GENE_OR_GENE_PRODUCT", 241, 249], ["GSK-3\u03b1", "PROTEIN", 31, 37], ["PI3K", "PROTEIN", 179, 183], ["Akt", "PROTEIN", 184, 187], ["GSK-3\u03b1", "PROTEIN", 188, 194], ["\u03b2", "PROTEIN", 195, 196], ["GSK-3\u03b2", "PROTEIN", 231, 237], ["lithium", "TEST", 9, 16], ["GSK", "TEST", 31, 34], ["inositol monophosphatases", "TEST", 39, 64], ["the electrolyte balance", "TEST", 93, 116]]], ["Curiously, GSK-3\u03b2 is required for template switching, a process seemingly indispensable for the production of coronaviral genomic RNA.", [["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 11, 17], ["GSK-3\u03b2", "PROTEIN", 11, 17], ["coronaviral genomic RNA", "RNA", 110, 133], ["template switching", "PROBLEM", 34, 52], ["coronaviral genomic RNA", "PROBLEM", 110, 133], ["coronaviral genomic RNA", "OBSERVATION", 110, 133]]], ["The inhibition of GSK-3\u03b2 prevents longer viral subgenomic mRNAs and the genomic RNA from being synthesized10.", [["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 18, 24], ["GSK-3\u03b2", "PROTEIN", 18, 24], ["viral subgenomic mRNAs", "RNA", 41, 63], ["genomic RNA", "RNA", 72, 83], ["GSK", "TEST", 18, 21], ["longer viral subgenomic mRNAs", "PROBLEM", 34, 63], ["the genomic RNA", "PROBLEM", 68, 83], ["subgenomic mRNAs", "OBSERVATION", 47, 63], ["genomic RNA", "OBSERVATION", 72, 83]]], ["Their production would require GSK-3\u03b2-dependent phosphorylation of the viral nucleocapsid and subsequent recruitment of helicase DDX1.Putative molecular mechanisms ::: DiscussionChloroquine (hydroxychloroquine) \u2013 which is thought to be effective in COVID-1911 \u2013 was shown to inhibit GSK-3\u03b2 and potentiate GSK-3\u03b2 inhibition caused by lithium.", [["DiscussionChloroquine", "CHEMICAL", 168, 189], ["hydroxychloroquine", "CHEMICAL", 191, 209], ["COVID-1911", "CHEMICAL", 249, 259], ["lithium", "CHEMICAL", 333, 340], ["DiscussionChloroquine", "CHEMICAL", 168, 189], ["hydroxychloroquine", "CHEMICAL", 191, 209], ["COVID-1911", "CHEMICAL", 249, 259], ["lithium", "CHEMICAL", 333, 340], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 31, 37], ["DDX1", "GENE_OR_GENE_PRODUCT", 129, 133], ["DiscussionChloroquine", "SIMPLE_CHEMICAL", 168, 189], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 191, 209], ["COVID-1911", "SIMPLE_CHEMICAL", 249, 259], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 283, 289], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 305, 311], ["lithium", "SIMPLE_CHEMICAL", 333, 340], ["GSK-3\u03b2", "PROTEIN", 31, 37], ["viral nucleocapsid", "PROTEIN", 71, 89], ["helicase DDX1", "PROTEIN", 120, 133], ["GSK-3\u03b2", "PROTEIN", 283, 289], ["GSK-3\u03b2", "PROTEIN", 305, 311], ["GSK", "TEST", 31, 34], ["dependent phosphorylation", "TREATMENT", 38, 63], ["the viral nucleocapsid", "PROBLEM", 67, 89], ["helicase DDX1", "TREATMENT", 120, 133], ["DiscussionChloroquine (hydroxychloroquine)", "TREATMENT", 168, 210], ["GSK", "TEST", 305, 308], ["lithium", "TREATMENT", 333, 340], ["viral nucleocapsid", "OBSERVATION", 71, 89], ["thought to be", "UNCERTAINTY", 222, 235]]], ["This indicates that mechanistic studies could investigate not only 0.5\u20131.2 mM lithium, but lithium with chloroquine as well.", [["lithium", "CHEMICAL", 78, 85], ["lithium", "CHEMICAL", 91, 98], ["chloroquine", "CHEMICAL", 104, 115], ["lithium", "CHEMICAL", 78, 85], ["lithium", "CHEMICAL", 91, 98], ["chloroquine", "CHEMICAL", 104, 115], ["lithium", "SIMPLE_CHEMICAL", 78, 85], ["lithium", "SIMPLE_CHEMICAL", 91, 98], ["chloroquine", "SIMPLE_CHEMICAL", 104, 115], ["mechanistic studies", "TEST", 20, 39], ["1.2 mM lithium", "TREATMENT", 71, 85], ["lithium", "TREATMENT", 91, 98], ["chloroquine", "TREATMENT", 104, 115]]], ["This also brings zinc to the spotlight since zinc inhibits GSK-3\u03b2 at micromolar concentrations12.Known antiviral activity in humans ::: DiscussionThere is some evidence that lithium may affect the course of viral diseases in humans.", [["zinc", "CHEMICAL", 17, 21], ["zinc", "CHEMICAL", 45, 49], ["GSK-3\u03b2", "CHEMICAL", 59, 65], ["lithium", "CHEMICAL", 174, 181], ["viral diseases", "DISEASE", 207, 221], ["zinc", "CHEMICAL", 17, 21], ["zinc", "CHEMICAL", 45, 49], ["lithium", "CHEMICAL", 174, 181], ["zinc", "SIMPLE_CHEMICAL", 17, 21], ["zinc", "SIMPLE_CHEMICAL", 45, 49], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 59, 65], ["humans", "ORGANISM", 125, 131], ["lithium", "SIMPLE_CHEMICAL", 174, 181], ["humans", "ORGANISM", 225, 231], ["GSK-3\u03b2", "PROTEIN", 59, 65], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 225, 231], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 225, 231], ["micromolar concentrations", "TEST", 69, 94], ["lithium", "TREATMENT", 174, 181], ["viral diseases in humans", "PROBLEM", 207, 231], ["antiviral activity", "OBSERVATION", 103, 121], ["viral diseases", "OBSERVATION", 207, 221]]], ["In a retrospective cohort study of patients with affective disorders a decrease in the rate of recurrent labial herpes was found in the lithium group (n = 177, p < 0.001) but not in the alternative treatment group (n = 59, p = 0.53)13.", [["labial", "ANATOMY", 105, 111], ["affective disorders", "DISEASE", 49, 68], ["labial herpes", "DISEASE", 105, 118], ["lithium", "CHEMICAL", 136, 143], ["lithium", "CHEMICAL", 136, 143], ["patients", "ORGANISM", 35, 43], ["labial", "ORGAN", 105, 111], ["herpes", "ORGANISM", 112, 118], ["lithium", "SIMPLE_CHEMICAL", 136, 143], ["patients", "SPECIES", 35, 43], ["a retrospective cohort study", "TEST", 3, 31], ["affective disorders", "PROBLEM", 49, 68], ["a decrease", "PROBLEM", 69, 79], ["recurrent labial herpes", "PROBLEM", 95, 118], ["decrease", "OBSERVATION_MODIFIER", 71, 79], ["labial", "ANATOMY", 105, 111], ["herpes", "OBSERVATION", 112, 118]]], ["In research previously conducted by Prof. J. Rybakowski at our hospital, lithium prevented labial herpes recurrence in thirteen out of 28 eligible psychiatric patients.", [["lithium", "CHEMICAL", 73, 80], ["herpes recurrence", "DISEASE", 98, 115], ["psychiatric", "DISEASE", 147, 158], ["lithium", "CHEMICAL", 73, 80], ["lithium", "SIMPLE_CHEMICAL", 73, 80], ["labial", "ORGAN", 91, 97], ["herpes", "ORGANISM", 98, 104], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["lithium", "TREATMENT", 73, 80], ["labial herpes recurrence", "PROBLEM", 91, 115], ["labial", "ANATOMY", 91, 97]]], ["Lithium also seemed to bring improvement in a proof-of-concept randomized double-blind placebo-controlled trial involving eleven healthy adults with recurrent HSV infections14 and in a randomized study of ten women with genital herpes conducted by the same research group.Other evidence for antiviral activity ::: DiscussionLiCl was shown to dose-dependently inhibit reovirus (10\u201360 mM)15 and food-and-mouth disease virus (10\u201340 mM)16.", [["Lithium", "CHEMICAL", 0, 7], ["HSV infections", "DISEASE", 159, 173], ["genital herpes", "DISEASE", 220, 234], ["DiscussionLiCl", "CHEMICAL", 314, 328], ["Lithium", "CHEMICAL", 0, 7], ["Lithium", "SIMPLE_CHEMICAL", 0, 7], ["HSV", "ORGANISM", 159, 162], ["women", "ORGANISM", 209, 214], ["DiscussionLiCl", "SIMPLE_CHEMICAL", 314, 328], ["reovirus", "ORGANISM", 367, 375], ["women", "SPECIES", 209, 214], ["-and-mouth disease virus", "SPECIES", 397, 421], ["HSV", "SPECIES", 159, 162], ["Lithium", "TREATMENT", 0, 7], ["blind placebo", "TREATMENT", 81, 94], ["recurrent HSV infections", "PROBLEM", 149, 173], ["a randomized study", "TEST", 183, 201], ["genital herpes", "PROBLEM", 220, 234], ["dependently inhibit reovirus", "PROBLEM", 347, 375], ["food", "TEST", 393, 397], ["mouth disease virus", "PROBLEM", 402, 421], ["infections", "OBSERVATION", 163, 173], ["evidence for", "UNCERTAINTY", 278, 290], ["antiviral activity", "OBSERVATION", 291, 309], ["mouth", "ANATOMY", 402, 407]]], ["At 5 mM concentration LiCl reduced the replication of avian leukosis virus subgroup J in chicken embryo fibroblast cells17.", [["embryo fibroblast cells", "ANATOMY", 97, 120], ["LiCl", "CHEMICAL", 22, 26], ["avian leukosis", "DISEASE", 54, 68], ["LiCl", "CHEMICAL", 22, 26], ["LiCl", "SIMPLE_CHEMICAL", 22, 26], ["avian leukosis virus", "ORGANISM", 54, 74], ["chicken", "ORGANISM", 89, 96], ["embryo fibroblast cells", "CELL", 97, 120], ["chicken embryo fibroblast cells17", "CELL_LINE", 89, 122], ["avian leukosis virus", "SPECIES", 54, 74], ["chicken", "SPECIES", 89, 96], ["avian leukosis virus", "SPECIES", 54, 74], ["chicken", "SPECIES", 89, 96], ["5 mM concentration LiCl", "TREATMENT", 3, 26], ["the replication", "TREATMENT", 35, 50], ["avian leukosis virus subgroup J in chicken embryo fibroblast cells", "TREATMENT", 54, 120], ["avian leukosis virus", "OBSERVATION", 54, 74], ["embryo fibroblast cells", "OBSERVATION", 97, 120]]], ["Yet, lithium at 50 \u00b5M concentration (12\u201320 times smaller than usually maintained in bipolar disorder) significantly reduced hepatitis C virus copy number (P = 0.0002) in supernatant from Huh7.5 cell culture18.", [["supernatant", "ANATOMY", 170, 181], ["Huh7.5 cell culture18", "ANATOMY", 187, 208], ["lithium", "CHEMICAL", 5, 12], ["bipolar disorder", "DISEASE", 84, 100], ["hepatitis", "DISEASE", 124, 133], ["lithium", "CHEMICAL", 5, 12], ["lithium", "SIMPLE_CHEMICAL", 5, 12], ["hepatitis C virus", "ORGANISM", 124, 141], ["Huh7.5 cell culture18", "CELL", 187, 208], ["Huh7.5 cell culture18", "CELL_LINE", 187, 208], ["hepatitis C virus", "SPECIES", 124, 141], ["lithium", "TREATMENT", 5, 12], ["bipolar disorder", "PROBLEM", 84, 100], ["significantly reduced hepatitis C virus copy", "PROBLEM", 102, 146], ["cell culture18", "TEST", 194, 208], ["reduced", "OBSERVATION_MODIFIER", 116, 123], ["hepatitis", "OBSERVATION", 124, 133]]], ["The latter study gives hope that lithium may indeed be efficient at clinically relevant levels.Safety and limitations ::: DiscussionLithium carbonate is an orphan drug widely used in the treatment of bipolar disorder.", [["lithium", "CHEMICAL", 33, 40], ["DiscussionLithium carbonate", "CHEMICAL", 122, 149], ["bipolar disorder", "DISEASE", 200, 216], ["lithium", "CHEMICAL", 33, 40], ["DiscussionLithium carbonate", "CHEMICAL", 122, 149], ["lithium", "SIMPLE_CHEMICAL", 33, 40], ["DiscussionLithium carbonate", "SIMPLE_CHEMICAL", 122, 149], ["The latter study", "TEST", 0, 16], ["lithium", "TREATMENT", 33, 40], ["DiscussionLithium carbonate", "TREATMENT", 122, 149], ["an orphan drug", "TREATMENT", 153, 167], ["bipolar disorder", "PROBLEM", 200, 216], ["bipolar disorder", "OBSERVATION", 200, 216]]], ["Its safety, when used correctly, is excellent19.", [["excellent", "OBSERVATION_MODIFIER", 36, 45]]], ["The main concern in the setting of an infectious disease unit would be the potential for interactions with other medication, possibly leading to the elevation of lithium levels and acute toxicity, mostly renal.", [["renal", "ANATOMY", 204, 209], ["lithium", "CHEMICAL", 162, 169], ["toxicity", "DISEASE", 187, 195], ["lithium", "CHEMICAL", 162, 169], ["lithium", "SIMPLE_CHEMICAL", 162, 169], ["renal", "ORGAN", 204, 209], ["an infectious disease unit", "PROBLEM", 35, 61], ["other medication", "TREATMENT", 107, 123], ["the elevation of lithium levels", "PROBLEM", 145, 176], ["acute toxicity", "PROBLEM", 181, 195], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infectious", "OBSERVATION", 38, 48], ["elevation", "OBSERVATION", 149, 158], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["toxicity", "OBSERVATION", 187, 195], ["renal", "ANATOMY", 204, 209]]], ["This may be prevented by monitoring serum lithium concentrations.", [["serum", "ANATOMY", 36, 41], ["lithium", "CHEMICAL", 42, 49], ["lithium", "CHEMICAL", 42, 49], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["lithium", "SIMPLE_CHEMICAL", 42, 49], ["monitoring serum lithium concentrations", "TEST", 25, 64]]], ["To our best knowledge, no interactions between lithium carbonate and ribavirin, lopinavir or ritonavir exist.", [["lithium carbonate", "CHEMICAL", 47, 64], ["ribavirin", "CHEMICAL", 69, 78], ["lopinavir", "CHEMICAL", 80, 89], ["ritonavir", "CHEMICAL", 93, 102], ["lithium carbonate", "CHEMICAL", 47, 64], ["ribavirin", "CHEMICAL", 69, 78], ["lopinavir", "CHEMICAL", 80, 89], ["ritonavir", "CHEMICAL", 93, 102], ["lithium carbonate", "SIMPLE_CHEMICAL", 47, 64], ["ribavirin", "SIMPLE_CHEMICAL", 69, 78], ["lopinavir", "SIMPLE_CHEMICAL", 80, 89], ["ritonavir", "SIMPLE_CHEMICAL", 93, 102], ["lithium carbonate", "TREATMENT", 47, 64], ["ribavirin", "TREATMENT", 69, 78], ["lopinavir", "TREATMENT", 80, 89], ["ritonavir", "TREATMENT", 93, 102]]], ["A randomized study in tenofovir-treated patients with HIV revealed that 24-week addition of lithium at target serum concentrations of 0.6\u20131.0 mmol/L was not associated with nephrotoxicity20.Safety and limitations ::: DiscussionLithium concentration may be, on the other hand, increased by loop or thiazide diuretics, angiotensin-converting enzyme inhibitors, and non-steroid anti-inflammatory drugs.", [["serum", "ANATOMY", 110, 115], ["tenofovir", "CHEMICAL", 22, 31], ["lithium", "CHEMICAL", 92, 99], ["nephrotoxicity", "DISEASE", 173, 187], ["DiscussionLithium", "CHEMICAL", 217, 234], ["thiazide", "CHEMICAL", 297, 305], ["angiotensin", "CHEMICAL", 317, 328], ["tenofovir", "CHEMICAL", 22, 31], ["lithium", "CHEMICAL", 92, 99], ["thiazide", "CHEMICAL", 297, 305], ["tenofovir", "SIMPLE_CHEMICAL", 22, 31], ["patients", "ORGANISM", 40, 48], ["HIV", "ORGANISM", 54, 57], ["lithium", "SIMPLE_CHEMICAL", 92, 99], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["DiscussionLithium", "SIMPLE_CHEMICAL", 217, 234], ["thiazide", "SIMPLE_CHEMICAL", 297, 305], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 317, 346], ["non-steroid anti-inflammatory drugs", "SIMPLE_CHEMICAL", 363, 398], ["patients", "SPECIES", 40, 48], ["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 54, 57], ["A randomized study", "TEST", 0, 18], ["tenofovir", "TREATMENT", 22, 31], ["HIV", "PROBLEM", 54, 57], ["lithium", "TREATMENT", 92, 99], ["serum concentrations", "TEST", 110, 130], ["nephrotoxicity", "PROBLEM", 173, 187], ["thiazide diuretics", "TREATMENT", 297, 315], ["angiotensin", "TREATMENT", 317, 328], ["converting enzyme inhibitors", "TREATMENT", 329, 357], ["non-steroid anti-inflammatory drugs", "TREATMENT", 363, 398]]], ["It is also is not clear if the use of lithium would be safe in acute disease accompanied by dehydration and unstable electrolyte levels.", [["lithium", "CHEMICAL", 38, 45], ["dehydration", "DISEASE", 92, 103], ["lithium", "CHEMICAL", 38, 45], ["lithium", "SIMPLE_CHEMICAL", 38, 45], ["lithium", "TREATMENT", 38, 45], ["acute disease", "PROBLEM", 63, 76], ["dehydration", "PROBLEM", 92, 103], ["unstable electrolyte levels", "PROBLEM", 108, 135], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["disease", "OBSERVATION", 69, 76], ["dehydration", "OBSERVATION", 92, 103], ["unstable", "OBSERVATION_MODIFIER", 108, 116], ["electrolyte levels", "OBSERVATION", 117, 135]]], ["Cardiotoxicity of lithium may occur not only with concentrations larger than 1.5 mmol/L, but also when levels of the ion rapidly change21.", [["Cardiotoxicity", "DISEASE", 0, 14], ["lithium", "CHEMICAL", 18, 25], ["lithium", "CHEMICAL", 18, 25], ["lithium", "SIMPLE_CHEMICAL", 18, 25], ["Cardiotoxicity of lithium", "TREATMENT", 0, 25]]], ["Although QTc prolongation is absent in most patients receiving lithium, QT dispersion ratio may increase; longer QT was also described in some cases.", [["QTc prolongation", "DISEASE", 9, 25], ["lithium", "CHEMICAL", 63, 70], ["lithium", "CHEMICAL", 63, 70], ["patients", "ORGANISM", 44, 52], ["lithium", "SIMPLE_CHEMICAL", 63, 70], ["patients", "SPECIES", 44, 52], ["QTc prolongation", "PROBLEM", 9, 25], ["lithium", "TREATMENT", 63, 70], ["QT dispersion ratio", "TEST", 72, 91], ["longer QT", "PROBLEM", 106, 115], ["increase", "OBSERVATION_MODIFIER", 96, 104]]], ["Concurrent use of lithium with chloroquine would need to be especially cautious in patients with QT prolongation.Safety and limitations ::: DiscussionIn the light of the reviewed data lithium appears as a possible candidate for therapy of COVID-19.", [["lithium", "CHEMICAL", 18, 25], ["chloroquine", "CHEMICAL", 31, 42], ["QT prolongation", "DISEASE", 97, 112], ["lithium", "CHEMICAL", 184, 191], ["lithium", "CHEMICAL", 18, 25], ["chloroquine", "CHEMICAL", 31, 42], ["lithium", "CHEMICAL", 184, 191], ["COVID-19", "CHEMICAL", 239, 247], ["lithium", "SIMPLE_CHEMICAL", 18, 25], ["chloroquine", "SIMPLE_CHEMICAL", 31, 42], ["patients", "ORGANISM", 83, 91], ["lithium", "SIMPLE_CHEMICAL", 184, 191], ["patients", "SPECIES", 83, 91], ["lithium", "TREATMENT", 18, 25], ["chloroquine", "TREATMENT", 31, 42], ["QT prolongation", "PROBLEM", 97, 112], ["lithium", "TREATMENT", 184, 191], ["therapy of COVID", "TREATMENT", 228, 244]]], ["We propose mechanistic investigation of the influence of lithium (0.5\u20131 mM) \u2013 alone and with chloroquine or other drugs \u2013 on the SARS-CoV-2 infection.Underlying data ::: Data availabilityAll data underlying the results are available as part of the article and no additional source data are required.Reporting guidelines ::: Data availabilityZenodo: PRISMA ScR checklist for \u2018Is lithium a potential treatment for the novel Wuhan (2019-nCoV) coronavirus?", [["lithium", "CHEMICAL", 57, 64], ["chloroquine", "CHEMICAL", 93, 104], ["infection", "DISEASE", 140, 149], ["lithium", "CHEMICAL", 378, 385], ["coronavirus", "DISEASE", 440, 451], ["lithium", "CHEMICAL", 57, 64], ["chloroquine", "CHEMICAL", 93, 104], ["lithium", "CHEMICAL", 378, 385], ["lithium", "SIMPLE_CHEMICAL", 57, 64], ["chloroquine", "SIMPLE_CHEMICAL", 93, 104], ["CoV-2", "ORGANISM", 134, 139], ["lithium", "SIMPLE_CHEMICAL", 378, 385], ["coronavirus", "ORGANISM", 440, 451], ["coronavirus", "SPECIES", 440, 451], ["SARS-CoV", "SPECIES", 129, 137], ["Wuhan (2019-nCoV) coronavirus", "SPECIES", 422, 451], ["lithium", "TREATMENT", 57, 64], ["chloroquine", "TREATMENT", 93, 104], ["other drugs", "TREATMENT", 108, 119], ["the SARS", "PROBLEM", 125, 133], ["CoV-2 infection", "PROBLEM", 134, 149], ["All data", "TEST", 187, 195], ["additional source data", "TEST", 263, 285], ["lithium a potential treatment", "TREATMENT", 378, 407], ["coronavirus", "PROBLEM", 440, 451], ["infection", "OBSERVATION", 140, 149]]], ["A scoping review\u2019.https://doi.org/10.5281/zenodo.363757422.Reporting guidelines ::: Data availabilityThe adapted reporting guidelines checklist is available under the terms of theCreative Commons Attribution 4.0 International license (CC-BY 4.0).", [["A scoping review", "TEST", 0, 16]]]], "PMC7198194": [["IntroductionIt is well known that all healthcare systems around the world occasionally unintentionally harm patients who are seeking help.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["Due to the importance of safety in ensuring a high quality of care, patient safety has become a fundamental aspect of the drive to improve quality, and this is receiving increasing interest from healthcare stakeholders in many countries [1].", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["Various stakeholders are responsible for ensuring that patient care is safely delivered and that patients are not harmed, including society overall, patients, clinicians including physicians and nurses, educators, administrators, researchers, professional bodies, governments and legislative bodies, and accrediting agencies [2].IntroductionLike the governments in other countries, the Korean government recognized that patient safety is an urgent threat to society and should be regarded as the cornerstone of health policy following several serious adverse events.", [["patient", "ORGANISM", 55, 62], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 149, 157], ["patient", "ORGANISM", 420, 427], ["patient", "SPECIES", 55, 62], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 149, 157], ["patient", "SPECIES", 420, 427], ["several serious adverse events", "PROBLEM", 535, 565]]], ["This act focuses on implementing a national reporting and learning system, the development of national healthcare standards and indexes, and formulating a strategic and comprehensive plan for patient safety every 5 years.", [["patient", "ORGANISM", 192, 199], ["patient", "SPECIES", 192, 199]]], ["In accordance with the act, the first national plan for patient safety (covering 2018 to 2022) was released in April 2018, which includes prioritizing R&D and supporting the process under both short-term and long-term national strategies [4].IntroductionThe design of the Korean national patient safety strategy was based on the classical top-down and essentially rational approach to policy-making.", [["patient", "ORGANISM", 56, 63], ["patient", "ORGANISM", 288, 295], ["patient", "SPECIES", 56, 63], ["patient", "SPECIES", 288, 295], ["long-term national strategies", "TREATMENT", 208, 237], ["the Korean national patient safety strategy", "TREATMENT", 268, 311]]], ["Many modern theorists have quoted empirical evidence from the field of policy studies to suggest that policies and actions are intertwined [5].", [["policy studies", "TEST", 71, 85]]], ["However, national policies should actually be created using a bottom-up approach as much as possible.", [["a bottom-up approach", "TREATMENT", 60, 80]]], ["The report from a study of developing the national plan for patient-safety R&D [6] also emphasized the importance of regularly surveying consumers and providers to explore their concerns and interests and their implications for national strategic planning and decision-making.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["a study", "TEST", 16, 23]]], ["Traditional survey and content analysis, and consensus panel methods with qualitative interviews are used where evidence is sparse or opinions are diverse.", [["Traditional survey", "TEST", 0, 18], ["content analysis", "TEST", 23, 39], ["consensus panel methods", "TEST", 45, 68]]], ["These methods require consultation with a large group from a geographically dispersed population, and their credibility is greatly dependent on the sampling method and panel composition [7].IntroductionThe recent and continuing rapid growth in user-generated text data shared in Web-based communities, posting boards, and social media has made it possible to study and analyze language at an unprecedented scale.", [["the sampling method", "TEST", 144, 163], ["greatly", "OBSERVATION_MODIFIER", 123, 130], ["dependent", "OBSERVATION_MODIFIER", 131, 140]]], ["The analysis of user-generated texts related to patient safety could reveal the topics of interest to various stakeholders.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["The analysis", "TEST", 0, 12]]], ["Natural language processing (NLP) facilitates the analysis of these data to extract meaning.", [["the analysis", "TEST", 46, 58], ["these data", "TEST", 62, 72]]], ["As an unsupervised NLP technique, topic-modeling based on latent Dirichlet allocation (LDA) is a statistical approach for discovering or identifying topics associated with certain words or phrases [11].", [["topic-modeling", "TREATMENT", 34, 48]]], ["One study [12] applied the topic-modeling technique to compare narrative reviews of online communities about hospitals to the domain of governmental hospital surveys.", [["One study", "TEST", 0, 9]]], ["Another study [13] applied an opinion-mining technique to social media to examine public opinions.IntroductionIn this study we applied a topic-modeling technique to explore text data on patient safety collected from Web-based user-generated texts.", [["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["Another study", "TEST", 0, 13], ["this study", "TEST", 113, 123], ["a topic-modeling technique", "TREATMENT", 135, 161], ["text data", "TEST", 173, 182]]], ["A thorough understanding of the interests, motivation, and behaviors of these Web-based healthcare stakeholders could make it possible to obtain voices from a bottom-up perspective.IntroductionThe next section provides brief background information about the topic-modeling approach and previous studies that have applied topic-modeling techniques in healthcare.", [["previous studies", "TEST", 286, 302]]], ["This is followed by a description of the study methodology and the main quantitative and qualitative results.", [["the study methodology", "TEST", 37, 58]]], ["We present qualitative results obtained by applying a tool for deep inspections of topic-term relationships, the WHO framework on the international classification of patient safety, and reviews of two external academic experts on patient safety.", [["patient", "ORGANISM", 166, 173], ["patient", "ORGANISM", 230, 237], ["patient", "SPECIES", 166, 173], ["patient", "SPECIES", 230, 237]]], ["Topic modeling is a statistical method for uncovering abstract topics from a collection of documents [14].", [["a statistical method", "TREATMENT", 18, 38]]], ["If a document is about the topic of \u2018institutional action on patient safety,\u2019 then terms such as \u2018action,\u2019 \u2018intervention,\u2019 \u2018inquiry,\u2019 \u2018standards,\u2019 \u2018prevention,\u2019 \u2018education,\u2019 \u2018report,\u2019 \u2018regulation,\u2019 and \u2018surveillance\u2019 will co-appear with high probabilities.", [["\u2018education", "DISEASE", 161, 171], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68]]], ["The name of the topic is abstracted and summarized by researchers (e.g., the topics \u2018law\u2019 or \u2018patient safety activities\u2019) based on the keywords that appear most frequently, because computer algorithms can find statistical clustering patterns of keywords but they cannot summarize the topics that keywords relate to.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101]]], ["In this study we used the LDA algorithm developed by Blei and colleagues [11,15] to obtain the parameters for every document (i.e., Web-based documents).Related Works ::: BackgroundText-mining methods such as topic modeling have many applications in various subjects related to healthcare.", [["this study", "TEST", 3, 13], ["the LDA algorithm", "TREATMENT", 22, 39], ["BackgroundText-mining methods", "TREATMENT", 171, 200]]], ["Regarding the applications to clinical documentation, one study [10] analyzed the free-text descriptions of a large repository of reports on patient safety events.", [["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["clinical documentation", "TEST", 30, 52], ["one study", "TEST", 54, 63]]], ["Another study [9] applied topic modeling to drug labeling in order to group drugs with similar safety concerns and/or therapeutic uses together.", [["Another study", "TEST", 0, 13], ["drug labeling", "TREATMENT", 44, 57], ["drugs", "TREATMENT", 76, 81]]], ["They used about 800 FDA-approved drug labels and generated 100 topics, each associated with a set of drugs based on their probability analysis.Related Works ::: BackgroundRegarding the literature-review applications, one study [16] applied topic modeling to perform automatic citation screening for systematic reviews.", [["drugs", "TREATMENT", 101, 106], ["their probability analysis", "TEST", 116, 142], ["one study", "TEST", 217, 226], ["automatic citation screening", "TEST", 266, 294], ["systematic reviews", "TEST", 299, 317]]], ["They also found that utilizing topic modeling dramatically decreased the workload of the screening phase.", [["the screening phase", "TEST", 85, 104]]], ["Another study [17] also used LDA to reduce the burden of screening for systematic reviews.", [["Another study", "TEST", 0, 13], ["LDA", "TEST", 29, 32], ["screening", "TEST", 57, 66], ["systematic reviews", "TEST", 71, 89]]], ["Those authors used the topics as another feature representation for documents having no manually assigned information, such as MeSH terms.Related Works ::: BackgroundRegarding the application to patient-generated text analysis, many studies have used topic modeling to analyze the opinions of online health communities in order to understand the needs and interests of patients.", [["patient", "ORGANISM", 195, 202], ["patients", "ORGANISM", 369, 377], ["patient", "SPECIES", 195, 202], ["patients", "SPECIES", 369, 377], ["text analysis", "TEST", 213, 226], ["many studies", "TEST", 228, 240], ["topic modeling", "TREATMENT", 251, 265]]], ["One study [18] used this method to detect patient noncompliance behaviors associated with a drug of interest from message posts on the most-popular French online forums.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["One study", "TEST", 0, 9], ["this method", "TREATMENT", 20, 31], ["patient noncompliance behaviors", "PROBLEM", 42, 73]]], ["Other studies [12,19] applied topic-extracting algorithms for LDA to capture what topics health consumers discuss when they are reviewing their health providers online.", [["Other studies", "TEST", 0, 13], ["topic-extracting algorithms", "TREATMENT", 30, 57], ["LDA", "TREATMENT", 62, 65]]], ["Those authors suggested that policymakers should focus on the measures of hospital quality that matter the most to patients and caregivers.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["Another study [20] applied automatic topic detection to explore hot topics in online communities about lung cancer, breast cancer, and diabetes.", [["lung cancer", "ANATOMY", 103, 114], ["breast cancer", "ANATOMY", 116, 129], ["lung cancer", "DISEASE", 103, 114], ["breast cancer", "DISEASE", 116, 129], ["diabetes", "DISEASE", 135, 143], ["lung cancer", "CANCER", 103, 114], ["breast cancer", "CANCER", 116, 129], ["Another study", "TEST", 0, 13], ["automatic topic detection", "TREATMENT", 27, 52], ["lung cancer", "PROBLEM", 103, 114], ["breast cancer", "PROBLEM", 116, 129], ["diabetes", "PROBLEM", 135, 143], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["breast", "ANATOMY", 116, 122], ["cancer", "OBSERVATION", 123, 129], ["diabetes", "OBSERVATION", 135, 143]]], ["The identified hot topics mainly covered symptoms, examinations, drugs, procedures, and complications.Related Works ::: BackgroundFew studies have analyzed the content on social media related to healthcare policy.", [["covered symptoms", "PROBLEM", 33, 49], ["examinations", "TEST", 51, 63], ["drugs", "TREATMENT", 65, 70], ["procedures", "TREATMENT", 72, 82], ["complications", "PROBLEM", 88, 101], ["Few studies", "TEST", 130, 141]]], ["Kang et al. [13] applied opinion-mining techniques to investigate public opinions about a new school-meals policy for preventing childhood obesity.", [["obesity", "DISEASE", 139, 146], ["childhood obesity", "PROBLEM", 129, 146], ["obesity", "OBSERVATION", 139, 146]]], ["They classified tweets into three categories: positive, negative, and neutral.", [["negative", "OBSERVATION", 56, 64]]], ["They found that negative opinions outnumbered positive ones and suggestions for future policy improvements.Defining Stakeholders and Web-Based Text as Data Sources ::: MethodsHealthcare stakeholders are generally defined as any person or party with an interest in the financing, implementation, or outcome of a service, practice, process, or decision made by another (e.g., healthcare or health policies).", [["person", "SPECIES", 228, 234]]], ["In this study we divided the stakeholders into four groups: consumers (e.g., patients, caregivers, and families), providers (e.g., physicians, nurses, and professional associations), governments (e.g., legislative bodies and accrediting agencies), and researchers.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["this study", "TEST", 3, 13]]], ["We searched Web-based communities and public websites for posting and news-sharing activities as well as opinions and information on patient safety.", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140]]], ["The 18 representative websites we found are listed according to stakeholder groups in Table 1: 1 large Korean mobile news portal of NAVER\u00ae; 6 websites of representative associations of physicians, nurses, and pharmacists; 10 sites of government organizations that have closely related to patient safety issues; and 1 large database portal website providing search services for academic and domestic research papers.Defining Stakeholders and Web-Based Text as Data Sources ::: MethodsWe collected text documents with timestamps indicating that they had appeared on a posting board or in a newsroom or announcement between January 2014 and September 2018.", [["patient", "ORGANISM", 288, 295], ["patient", "SPECIES", 288, 295], ["government organizations", "TREATMENT", 234, 258], ["timestamps", "TREATMENT", 516, 526], ["portal", "ANATOMY", 122, 128], ["portal", "ANATOMY", 332, 338]]], ["This period ranged from 1 year before establishment of the Patient Safety Act to the time when data collection was started for this study, and spanned 4 years and 9 months.", [["data collection", "TEST", 95, 110], ["this study", "TEST", 127, 137]]], ["We retrieved text documents by applying several inclusion keywords [e.g., patient safety, adverse event(s), hospital, healthcare institution, harm, injury, errors, accident, malpractice, misuse, side effects, mistakes, malfunction, and defect] and exclusion keywords (e.g., pet, bid, recruitment, ad, assault, strike, new product, new technology, and development).", [["injury", "DISEASE", 148, 154], ["accident", "DISEASE", 164, 172], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["injury", "PROBLEM", 148, 154], ["side effects", "PROBLEM", 195, 207], ["mistakes, malfunction, and defect", "PROBLEM", 209, 242]]], ["Fig. 1shows the construct of documents and words retrieved by stakeholder groups.Defining Stakeholders and Web-Based Text as Data Sources ::: MethodsFor further data cleansing, we reviewed all of the document titles and excluded less-relevant documents manually.", [["Methods", "TREATMENT", 142, 149]]], ["Text data preprocessing was divided into words using a Korean NLP package, and special characters, pre and post position, and capital letters were treated consistently.", [["a Korean NLP package", "TREATMENT", 53, 73]]], ["We also used a synonyms dictionary.", [["a synonyms dictionary", "TREATMENT", 13, 34]]], ["This process identified 2,933 words that were used to develop a document-term matrix.Defining Stakeholders and Web-Based Text as Data Sources ::: MethodsThe topics were extracted by implementing LDA using the open-source software package topicmodels in R software [21].", [["matrix", "CELLULAR_COMPONENT", 78, 84], ["Methods", "TREATMENT", 146, 153]]], ["The LDA model was estimated using the maximum likelihood as described by Gr\u00fcn and Hornik [21].", [["The LDA model", "TEST", 0, 13]]], ["To estimate a posterior distribution, it is using Gibbs sampling as a special case of Markov-chain Monte Carlo methods, which reportedly often yields relatively simple algorithms for approximate inferencing in high-dimensional models such as LDA [23].", [["Gibbs sampling", "TEST", 50, 64], ["posterior", "ANATOMY_MODIFIER", 14, 23]]], ["According to Phan et al. [23], the estimation accuracy changes slightly with the number of Gibbs sampling iterations, with the iterations being fast and yielding stable results after a burn-in period.", [["the estimation accuracy", "TEST", 31, 54], ["stable", "OBSERVATION_MODIFIER", 162, 168]]], ["We therefore set alpha to 1.2195, and beta was freely estimated by conducting the test with the following setting: 2,000 iterations, burn-in period of 1,000 iterations, and a thinning interval of 500 iterations.", [["beta", "GENE_OR_GENE_PRODUCT", 38, 42], ["alpha to 1.2195, and beta", "PROTEIN", 17, 42]]], ["(Supplement material A).Defining Stakeholders and Web-Based Text as Data Sources ::: MethodsFor the analysis at the level of topics, we formulated more-sophisticated generative models that incorporated parameters describing the changes in the prevalence of topics over time.", [["Methods", "TREATMENT", 85, 92], ["the analysis", "TEST", 96, 108]]], ["The analysis was based on a post-hoc examination of the estimates of topic proportions produced by the model.", [["The analysis", "TEST", 0, 12], ["a post-hoc examination", "TEST", 26, 48]]], ["Being able to identify the hot topics at a particular period is useful when considering the trends in the concerns of stakeholders for performing future strategic planning, by providing quantitative measures of the prevalence of particular kinds of topics.", [["strategic planning", "TREATMENT", 153, 171]]], ["To find topics that consistently increased or decreased in popularity from 2014 to 2018, we conducted a linear trend analysis of a topic proportion on a quarterly basis, using the same single sample as in these analyses.Qualitative Validation of the Extracted Topics ::: MethodsA topic model yields a word list of topics, which may be viewed as keywords of that topic.", [["these analyses", "TEST", 205, 219], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["decreased", "OBSERVATION_MODIFIER", 46, 55]]], ["Although the present authors already had the required expertise, we adopted several methods to stimulate an objective inference process.Qualitative Validation of the Extracted Topics ::: MethodsFirst, we used the Web-based interactive visualization tool LDAvis, which enables deep inspections of the topic\u2013term relationships in an LDA model [24].", [["several methods", "TREATMENT", 76, 91], ["an LDA model", "TEST", 328, 340]]], ["The LDAvis tool provided a global view of the topics through their prevalence rates and similarities to each other in a compact space.", [["The LDAvis tool", "TEST", 0, 15]]], ["For example, when a doctor and the associated hospital were accused of illegal orthopedic surgeries being performed by an unlicensed person, relevant news and social responses increased with concerns about patient safety.", [["patient", "ORGANISM", 206, 213], ["person", "SPECIES", 133, 139], ["patient", "SPECIES", 206, 213], ["illegal orthopedic surgeries", "TREATMENT", 71, 99]]], ["Third, we asked two expert academics working on patient safety to review our inferred themes: an oncology specialist and an emergency medicine professor affiliated to an academic tertiary hospital and university.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["We explained our research aims, methods, and results, and then asked the two experts to independently score their level of agreement using a 5-point scale [from 1 (strongly disagree) to 5 (strongly agree)] and provide comments and feedback, which were used when confirming and revising the topic themes.", [["a 5-point scale", "TREATMENT", 139, 154]]], ["In this qualitative step we inspected the properties of the text and disambiguated between word senses to identify the themes that were obscured by the topic word list.Topic-Modeling Results ::: ResultsApplying the statistical method of Griffiths and Steyvers [22] to calculate harmonic means revealed that the optimal number of topics was 41.", [["harmonic means", "TEST", 278, 292]]], ["Through the exploration and inspection of the topic-term relationships, we identified 9, 20, 8, and 4 topics for the consumer, provider, government, and researcher groups, respectively.", [["the exploration", "TEST", 8, 23], ["inspection", "TEST", 28, 38]]], ["Several topics were temporally aligned with specific social events, while other topics with mixed meanings showed weak word\u2013topic relationships.", [["weak word\u2013topic relationships", "PROBLEM", 114, 143]]], ["We present only 10 of the keywords having higher probabilities under each topic.Topic-Modeling Results ::: ResultsRegarding the topics that consistently increased and decreased in popularity, five of the topics showed significant increasing trends while another five showed decreasing trends (both P = 0.05).", [["significant increasing trends", "PROBLEM", 218, 247], ["P", "TEST", 298, 299], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["decreased", "OBSERVATION_MODIFIER", 167, 176], ["significant", "OBSERVATION_MODIFIER", 218, 229], ["increasing", "OBSERVATION_MODIFIER", 230, 240], ["decreasing", "OBSERVATION_MODIFIER", 274, 284]]], ["The hot topics were \u2018management of regular check-ups,\u2019 \u2018newborn death at a neonatal ICU,\u2019 \u2018hospital infection control,\u2019 \u2018infusion-related infection,\u2019 and \u2018patient safety precaution alert.\u2019", [["death", "DISEASE", 64, 69], ["infection", "DISEASE", 100, 109], ["infection", "DISEASE", 138, 147], ["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["hospital infection control", "TREATMENT", 91, 117], ["related infection", "PROBLEM", 130, 147], ["infection", "OBSERVATION", 138, 147]]], ["The cold topics were \u2018adverse drug reaction(s),\u2019 \u2018government policy,\u2019 \u2018nursing service,\u2019 \u2018illegal surgeries,\u2019 and \u2018fall risk assessment.\u2019Qualitative Validation Results ::: ResultsTwo reviewers agreed upon 35 themes that the research team assigned to each topic.", [["adverse drug reaction", "DISEASE", 22, 43], ["illegal surgeries", "TREATMENT", 90, 107], ["fall risk assessment", "TEST", 115, 135]]], ["These topics showed characteristics of having no or only a very small number of salient words in the word distributions and small proportions per document.", [["very", "OBSERVATION_MODIFIER", 59, 63], ["small", "OBSERVATION_MODIFIER", 64, 69], ["salient words", "OBSERVATION", 80, 93], ["word distributions", "OBSERVATION", 101, 119], ["small", "OBSERVATION_MODIFIER", 124, 129]]], ["The research team agreed that several perspectives were mixed, and it was difficult to name a single theme: one of the reviewers thought it was about general characteristics of patient safety, while the other reviewer suggested that it was about the safety infrastructure.", [["patient", "ORGANISM", 177, 184], ["patient", "SPECIES", 177, 184]]], ["However, performing a qualitative review of the original text revealed that its main content was about initiating or posting \u2018education of medical staff and personnel on patient safety\u2019 at the hospital level and at the collective level of the Korean Hospital Association.", [["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 170, 177], ["main content", "OBSERVATION", 80, 92]]], ["The qualitative analysis resulted in the themes of 6 topics being revised and the remaining 35 being confirmed.DiscussionThis study explored whether the text data on patient safety collected from Web-based, user-generated documents represent the specific concerns of various healthcare stakeholders.", [["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 166, 173], ["The qualitative analysis", "TEST", 0, 24], ["This study", "TEST", 121, 131], ["the text data", "TEST", 149, 162]]], ["We found that the text data were useful for inferring the latent concerns of consumers, providers, government bodies, and researchers, as well as changes therein over time.", [["the text data", "TEST", 14, 27]]], ["In particular, several important pieces of legislation have been introduced and improvements in the social system related to patient safety have been made over the last 5 years in Korea.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["several", "OBSERVATION_MODIFIER", 15, 22], ["important", "OBSERVATION_MODIFIER", 23, 32], ["pieces", "OBSERVATION_MODIFIER", 33, 39], ["legislation", "OBSERVATION", 43, 54]]], ["We found that infection control by medical institutions was the most common concern among the healthcare stakeholders, and there were trends in the changes in concerns about medication errors, adverse drug reactions, and falls between before and after the Patient Safety Act was enacted.", [["infection", "DISEASE", 14, 23], ["adverse drug reactions", "DISEASE", 193, 215], ["falls", "DISEASE", 221, 226], ["infection control", "TREATMENT", 14, 31], ["medication errors", "PROBLEM", 174, 191], ["adverse drug reactions", "PROBLEM", 193, 215], ["infection", "OBSERVATION", 14, 23]]], ["These findings and methods could be used as the basis for a bottom-up approach to national strategic planning on patient safety.DiscussionConsidering the common concern of the stakeholders, the Middle East respiratory syndrome outbreak in early 2015 [26] and infusion-related infections from late 2017 thorough to the middle of 2018 received considerable attention as a topic related to institutional infection control.", [["respiratory syndrome", "DISEASE", 206, 226], ["infections", "DISEASE", 276, 286], ["infection", "DISEASE", 401, 410], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["a bottom-up approach", "TREATMENT", 58, 78], ["the Middle East respiratory syndrome", "PROBLEM", 190, 226], ["infusion", "TREATMENT", 259, 267], ["related infections", "PROBLEM", 268, 286], ["institutional infection control", "TREATMENT", 387, 418], ["Middle", "ANATOMY_MODIFIER", 194, 200], ["respiratory syndrome", "OBSERVATION", 206, 226], ["infection", "OBSERVATION", 401, 410]]], ["Healthcare facilities increased their efforts in infection control and the government implemented a patient safety precaution alert system in late 2017 and comprehensive measures for preventing healthcare-associated infections, such as by releasing guidelines, training, and performing epidemic investigations and surveillance.", [["infection", "DISEASE", 49, 58], ["infections", "DISEASE", 216, 226], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["infection control", "TREATMENT", 49, 66], ["comprehensive measures", "TREATMENT", 156, 178], ["associated infections", "PROBLEM", 205, 226], ["epidemic investigations", "TEST", 286, 309], ["surveillance", "TEST", 314, 326], ["infections", "OBSERVATION", 216, 226]]], ["One possible reason is that hospital infections represent strictly confidential information for each hospital, and so both the size and types of problems are unknown.", [["infections", "DISEASE", 37, 47], ["hospital infections", "PROBLEM", 28, 47], ["size", "OBSERVATION_MODIFIER", 127, 131]]], ["Most of the cases are treated internally, and the information becomes public only if several patients got unexpected infection problems or died simultaneously.", [["infection", "DISEASE", 117, 126], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["unexpected infection problems", "PROBLEM", 106, 135], ["infection", "OBSERVATION", 117, 126]]], ["Other unusual situations, such as the increased cases of hepatitis C virus at a clinic in 2015 [27], become public after they are investigated by public health authorities.", [["hepatitis C virus", "DISEASE", 57, 74], ["hepatitis C virus", "ORGANISM", 57, 74], ["hepatitis C virus", "SPECIES", 57, 74], ["hepatitis C virus", "SPECIES", 57, 74], ["Other unusual situations", "PROBLEM", 0, 24], ["hepatitis C virus", "PROBLEM", 57, 74]]], ["Such cases are often due to the lack of routine measurements and patient monitoring, and reviewing and improving everyday healthcare practices.DiscussionRegarding changes in stakeholder concerns between before and after the Patient Safety Act was enacted in January 2015, topics of adverse drug reactions, medication errors, and falls surged during 2014 and in early 2015, but these topics typically decreased after the legislation.", [["adverse drug reactions", "DISEASE", 282, 304], ["falls", "DISEASE", 329, 334], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["routine measurements", "TEST", 40, 60], ["patient monitoring", "TEST", 65, 83], ["adverse drug reactions", "PROBLEM", 282, 304], ["medication errors", "PROBLEM", 306, 323], ["decreased", "OBSERVATION_MODIFIER", 400, 409]]], ["This finding could be explained by two ways: (i) that the act and subsequent measures were effective in decreasing the occurrence of harmful events in healthcare settings, although this is less likely over a short period, but also there is no evidence for this, and (ii) the presence of the interests tilting phenomena, but this is still vague and needs further follow-up and investigation.DiscussionWe did not find any trends in the most- or least-popular research topics.", [["the interests tilting phenomena", "PROBLEM", 287, 318], ["investigation", "TEST", 376, 389], ["less likely", "UNCERTAINTY", 189, 200], ["no evidence for", "UNCERTAINTY", 240, 255], ["tilting phenomena", "OBSERVATION", 301, 318]]], ["Unlike other stakeholders, the research topics were similar and showed little changes over time.", [["little", "OBSERVATION_MODIFIER", 71, 77]]], ["The study topics were a hospital\u2019s patient safety activities and the perceptions, attitude, and awareness of clinicians and how they communicated patient safety issues.", [["patient", "ORGANISM", 35, 42], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 35, 42], ["patient", "SPECIES", 146, 153], ["The study", "TEST", 0, 9]]], ["These results are similar to those of Cho et al. [28], who performed a systematic review of domestic papers on patient safety 6 years ago.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118]]], ["That review found that research topics were limited to descriptive surveys of safety cultures and communication issue in a hospital and the perceptions of clinicians.", [["safety cultures", "TEST", 78, 93]]], ["The results of that study showed support the results obtained in our topic-modeling approach.DiscussionFinally, this study adopted the topic-modeling method to explore the heterogeneous concerns of healthcare stakeholders.", [["that study", "TEST", 15, 25], ["this study", "TEST", 112, 122], ["heterogeneous", "OBSERVATION_MODIFIER", 172, 185]]], ["However, a few studies have used topic modeling and social media to capture public opinions about healthcare policy from different user groups.", [["a few studies", "TEST", 9, 22]]], ["Traditional ways to obtain a consensus from stakeholders including using group panels with the RAND Appropriate Method [29] or the Delphi technique [30].", [["group panels", "TEST", 73, 85]]], ["We believe that a text-mining technique such as topic modeling that we have applied has great potential in obtaining useful clues and insights hidden in large text data sets.ConclusionsA common concern among stakeholders was hospital infection control, ranging from nosocomial infections to those brought in by visiting patients.", [["infection", "DISEASE", 234, 243], ["nosocomial infections", "DISEASE", 266, 287], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 320, 328], ["a text-mining technique", "TREATMENT", 16, 39], ["topic modeling", "TREATMENT", 48, 62], ["hospital infection control", "PROBLEM", 225, 251], ["nosocomial infections", "PROBLEM", 266, 287]]], ["Government policies and systemic approaches to patient safety were highlighted by different stakeholders.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["systemic approaches", "TREATMENT", 24, 43]]], ["The new understanding about stakeholders will enhance the ability to harmonize policies related to patient safety, by incorporating factors such as culture, organizational structures, and modes of operation as well as wider political processes.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["culture", "TEST", 148, 155], ["operation", "TREATMENT", 197, 206], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["In addition, our research methods and the results obtained could be used when designing a national patient safety strategy as a policy created using a bottom-up approach as well as when setting research priorities for academia.ContributorsI.C. conceived the study.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["a bottom-up approach", "TREATMENT", 149, 169], ["academia", "PROBLEM", 218, 226], ["the study", "TEST", 254, 263]]], ["M.L. and Y.J.K. extracted and processed the data, and conducted the analyses.", [["the data", "TEST", 40, 48], ["the analyses", "TEST", 64, 76]]], ["All of the authors commented on the manuscript drafts and then gave their approval for the final version to be published.", [["the final version", "TREATMENT", 87, 104]]]]}